molecular pharmaceutics

Article



CORNELL UNIVERSITY LIBRARY

Subscriber access provided by CORNELL UNIVERSITY LIBRARY

Addressing the Biochemical Foundations of a Glucosebased "Trojan horse"–strategy to Boron Neutron Capture Therapy: From Chemical Synthesis to In Vitro Assessment

Jelena Matovi#, Juulia Järvinen, Helena C. Bland, Iris K Sokka, Surachet Imlimthan, Ruth Mateu Ferrando, Kristiina M. Huttunen, Juri Timonen, Sirpa Peräniemi, Olli Aitio, Anu J. Airaksinen, Mirkka Sarparanta, Mikael P. Johansson, Jarkko Rautio, and Filip S. Ekholm

> *Mol. Pharmaceutics*, **Just Accepted Manuscript •** DOI: 10.1021/ acs.molpharmaceut.0c00630 • Publication Date (Web): 11 Aug 2020

> > Downloaded from pubs.acs.org on August 19, 2020

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Addressing the Biochemical Foundations of a Glucose-based "Trojan horse"–strategy to Boron Neutron Capture Therapy: From Chemical Synthesis to *In Vitro* Assessment

Jelena Matović,^{1, \phi} Juulia Järvinen,^{2, \phi} Helena C. Bland,¹ Iris K. Sokka,¹ Surachet Imlimthan,¹ Ruth Mateu Ferrando,¹ Kristiina M. Huttunen,² Juri Timonen,² Sirpa Peräniemi,² Olli Aitio,³ Anu J. Airaksinen,^{1,4} Mirkka Sarparanta,¹ Mikael P. Johansson,^{1,5} Jarkko Rautio² and Filip S. Ekholm^{1*}

¹Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland

² School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland

³ Glykos Finland Ltd., Viikinkaari 6, FI-00790 Helsinki, Finland

⁴ Turku PET Centre, Department of Chemistry, University of Turku, P.O. Box 52, FI-20521 Turku, Finland

⁵ Helsinki Institute of Sustainability Science, HELSUS, FI-00014 Helsinki, Finland

[•] Equal contributions

Contact: filip.ekholm@helsinki.fi

Table of content graphic



Abstract

Boron Neutron Capture Therapy (BNCT) for cancer is on the rise worldwide due to recent developments of in-hospital neutron accelerators which are expected to revolutionize patient treatments. There is an urgent need for improved boron delivery agents and herein we have focused on studying the biochemical foundations upon which a successful GLUT1-targeting strategy to BNCT could be based. By combining synthesis and molecular modelling with affinity and cytotoxicity studies, we unravel the mechanisms behind the considerable potential of appropriately designed glucoconjugates as boron delivery agents for BNCT. In addition to addressing the biochemical premises of the approach in detail, we report on a hit glucoconjugate which displays good cytocompatibility, aqueous solubility, high transporter affinity, and, crucially, an exceptional boron delivery capacity in the *in vitro* assessment thereby pointing towards the significant potential embedded in this approach.

Keywords: boron neutron capture therapy, cancer therapeutics, carbohydrates, glucose transporters, medicinal chemistry, drug delivery

1. Introduction

As one of the leading causes of morbidity and mortality on a global scale, cancer is a significant societal economic burden with annual global costs of 723–930 billion euros. Head and neck cancers account for up to 10 % of all cancers with 630 000 new cases annually diagnosed worldwide.^{1,2} Despite traditional treatments featuring surgery, radiation and chemotherapy, all of which are arduous for the patients, many of these cancers recur. In head and neck cancers, the inoperable recurrent ones are accompanied by a poor survival rate with a mean survival time of only a few months.³ A number of novel treatment strategies have recently gained ground. These include antibody-drug conjugates,⁴ proton therapy,^{5,6} and, especially, boron neutron capture therapy (BNCT).⁷ BNCT represents one of the most promising non-invasive binary treatment modalities for head and neck cancers since it can eradicate cancer cells while simultaneously sparing healthy cells (the basis of our approach is displayed in Figure 1).^{8,9} The selectivity in BNCT arises from a two-fold effect. First, only cells with a sufficient concentration of ¹⁰B-atoms are destroyed and, second, the external neutron beam can be applied to a narrow and highly specific area where malignant cells are present. Previously, the applications of, and interest in, clinical BNCT have been hampered by the need for nuclear reactors, as a neutron source, and the poor properties of clinically used boron delivery agents. In recent years, new in-hospital neutron accelerators¹⁰ have emerged thus revolutionizing the clinical aspects of patient treatments; a renewed interest in the BNCT field has been invoked – now, the final challenge to solve is that of developing improved boron delivery agents.



Figure 1. The principles of our approach to BNCT. Blue dots represent boron atoms while grey dots represent carbon atoms in the *ortho*-carboranylmethyl moiety.

An optimally functioning delivery agent for BNCT should display a minimal systemic toxicity, a cellular uptake of 20–35 µg/g of tumour (i.e. ppm range), and tumour/normal tissue (T/N) and tumour/blood (T/B) ratios above 3:1, with higher ratios naturally desirable. Combining these different aspects into one single delivery agent has proved challenging. Despite the large number of delivery agents (amino acids, carbohydrates, porphyrins, antibody-boron conjugates, polymers, peptides, liposomes and nanoparticles) evaluated in the literature,^{11–13} only three are in clinical use. These are sodium borocaptate (BSH), boronophenylalanine (BPA and its fructose-complex) and decahydrodecaborate (GB-10). None of them exhibit optimal properties. BPA has poor water solubility, contains only one boron atom/delivered molecule, and gives poor T/B- and T/N-ratios.^{14,15} BSH¹⁶ and GB-10¹⁷ lack active targeting and uptake mechanisms and have an ionic nature which may cause undesired interactions with other biomolecules in a biological context.

Page 5 of 47

Molecular Pharmaceutics

The intrinsic properties of carbohydrates, i.e., high aqueous solubility, low systemic toxicity and high biocompatibility make them seemingly ideal candidates for clinical BNCT. Polysaccharide and oligosaccharide carriers are, however, sub-optimal from a BNCT-perspective: polysaccharides are constrained to the extracellular matrix while oligosaccharides display low lectin-binding affinities. Thus, we have chosen to focus on monosaccharides in combination with carbohydrate transporters, glucose transporters (GLUTs and SGLTs) in particular.

Glucose is an essential nutrient for mammalian cells. An increased expression of GLUTs and SGLTs, especially GLUT1, has been observed in head and neck cancers.¹⁸ The basis for this increase is the switch in glucose metabolism which in cancer cells proceeds by an inefficient aerobic glycolysis route in contrast to the oxidative metabolism in healthy non-cancerous cells.¹⁹ This inefficient metabolic pathway leads to a substantial increase in glucose uptake which allows the cancer cells to grow rapidly and proliferate.²⁰ Exploiting this "Warburg effect", named after Nobel laureate Otto Heinrich Warburg, provides the foundation for the development of novel glucose-based "Trojan horses" for clinical BNCT. Before reaching the end stages of the development process (*in vivo*-studies with/without neutron sources), the biochemical foundations of the approach need to be addressed in detail. In this regard, it is important to note that concerns have been raised regarding the effects of glucoconjugates on glucose metabolism in healthy cells, the possible incorporation of metabolic products into other biomolecules, and the competition for the transporters with the high glucose levels found in blood.²¹ Therefore, for a GLUT targeting approach to be successful, it is crucial to address these issues already at the design stage.



Figure 2. Two of the delivery agents in clinical use (left box) and the 6-*O*-*ortho*-carboranylmethyl glucoconjugates prepared in the current study (right box). Blue dots represent boron atoms while grey dots represent carbon atoms in the carboranyl moiety.

To this end, we have designed and synthesized three glucoconjugates bearing an *ortho*carboranylmethyl substituent. The carboranyl provides ten boron nuclei per delivery molecule in a charge-neutral, chemically stable form, and is thus highly suitable for the purposes of BNCT. In addition, a neutral and hydrophobic boron cluster should be advantageous when aiming for transport through a transmembrane protein since possible unfavourable interactions between charged boron clusters and amino acids can be avoided.²² Figure 2 shows the three 6-*O*-carboranylmethyl glucoconjugates targeted; the hemiacetal and both methyl glycosides. The attachment of boron clusters at the 6th position in glucose is rare in the scientific literature and conjugates with chargeneutral boron clusters have not been prepared earlier.^{23,24} A modification at this site will, however, remove the concerns regarding interference with glucose metabolism and incorporation into other biomolecules through the glycolysis route; the 6-*O*-carboranylmethyl glucoconjugates are no longer substrates for the glycolysis route in which the first transformation is a phosphorylation at the 6th position.²⁵

In addition to synthesizing the glucoconjugates and conducting the most detailed structural characterization of such conjugates to date, we have addressed the biochemical foundations of the GLUT1-targeting approach through a preliminary, yet, comprehensive *in vitro* evaluation study

featuring cytotoxicity, computational/experimental receptor affinity, and cellular uptake experiments in the relevant human head and neck cancer cell line CAL 27 (oral adenosquamous carcinoma cell line). To our satisfaction, the new glucoconjugates display a significantly stronger binding affinity to GLUT1 than glucose. This shows that the previous fear regarding their competition with the high levels of free glucose in blood has been unfounded. Moreover, the glucoconjugates display a boron delivery capacity 40 times higher than the best agents currently in clinical use – showing that there is considerable potential imbedded in this alternative approach.

2. Experimental section

2.1 Synthesis and structural characterization

Reaction solvents were purified by the VAC vacuum solvent purification system prior to use when dry solvents were needed. All reactions containing moisture- or air-sensitive reagents were carried out under an argon atmosphere. All reagents were purchased from commercial sources. The NMR spectra were recorded with a Bruker Avance III NMR spectrometer operating at 500.13 MHz (¹H: 500.13 MHz, ¹³C: 125.76 MHz, ¹¹B: 160.46 MHz). The probe temperature during the experiments was kept at 23 °C. All products were characterized by utilization of the following 1D-techniques: ¹H, ¹³C, ¹¹B and 1D-TOCSY and the following 2D-techniques: Ed-HSQC, HMBC and COSY by using pulse sequences provided by the instrument manufacturer. Chemical shifts are expressed on the δ scale (in ppm) using TMS (tetramethylsilane), residual chloroform, methanol or 15% BF₃ in CDCl₃ (¹¹B NMR) as internal standards. Coupling constants have been obtained through spectral simulations with the Perch Peak Research software, are given in Hz and provided only once, when first encountered. Coupling patterns are given as s (singlet), d (doublet), t (triplet) etc. HRMS were recorded using Bruker Micro Q-TOF with ESI (electrospray ionization) operated in positive mode. The purity of the compounds were determined to be > 95 % in all cases. TLC was performed on aluminum sheets precoated with silica gel 60 F254 (Merck). Flash chromatography was carried out

on silica gel 40. Spots were visualized by UV, followed by spraying the TLC plates with a solution of H_2SO_4 :MeOH (1:4) and heating.

General experimental procedures

General Procedure for selective silylation of the 6-OH group in glucopyranoses: *Tert*butyldimethylsilyl chloride (1.35 equiv.) was added portion-wise to a solution of D-glucose (1 equiv.) in pyridine (10 ml/g of starting material) at 0 °C. The mixture was brought to rt and stirred for 21 h. The solvent was removed *in vacuo* and the crude product was purified by column chromatography (DCM:MeOH 7:1), the solvents were removed and the corresponding silylated glycopyranose was dried on the vacuum line.

General Procedure for selective silvlation of the 6-OH group in glucopyranosides: The corresponding Methyl D-glucopyranoside (1 equiv.) was dissolved in dry DMF (10 ml/g of starting material) at 0 °C under an atmosphere of argon. Imidazole (1.5 equiv.) and the *tert*-butyldimethylsilyl chloride (1.35 equiv.) were added and the reaction mixture was brought to rt. The mixture was stirred o/n. The reaction was quenched by the addition of MeOH (0.25 ml/g of starting material) and concentrated *in vacuo*. The crude product was purified by column chromatography (DCM:MeOH 7:1), the solvents were removed and the corresponding silvlated glycoside was dried on the vacuum line.

General Procedure for alkylation of free hydroxyl groups: The partially protected glucoside/glucopyranose (1 equiv.) was dissolved in dry DMF (2 ml/100 mg of starting material) under an atmosphere of argon. The solution was cooled on an ice bath and NaH (1.9 equiv.) was added. The reaction mixture was stirred for 15 min., then brought to rt and stirred for a further 10 min. The corresponding bromide (1.5 equiv./free OH-group) was added and the resulting mixture was

Molecular Pharmaceutics

stirred for 1–4 h, quenched with MeOH (0.4 ml/mmol of starting material), diluted with DCM (4 ml/100 mg) and washed with a satd. NaHCO₃-solution. The organic phase was separated and the aqueous phase was extracted with DCM (3 x 3 ml/100 mg). The organic phases were combined and washed with brine (3 ml/100 mg), dried over Na₂SO₄, filtered and concentrated. The crude product was purified by column chromatography (EtOAc:Hexane 1:8), the solvents were removed and the corresponding alkylated glycoside was dried on the vacuum line.

General procedure for deprotection of silyl protective groups: To a solution containing the protected glycoside (1 equiv.) in dry THF (3 ml/200 mg of starting material) at 0 °C, HF-pyridine (18 μ l/0.03 mmol of starting material) was added. The resulting mixture was brought to rt and stirred for 20 h. The reaction mixture was diluted with DCM (30 ml/0.5 g of starting material) and quenched by the addition of a satd. NaHCO₃-solution (20 ml/200 mg of starting material). The aqueous phase was extracted with DCM (3 x 20 ml) and the organic phases were combined and washed with brine (20 ml/500 mg of starting material). The combined organic phase was dried over Na₂SO₄, filtered and concentrated. The crude product was purified by column chromatography (Hexane:EtOAc 2:1), the solvents were removed and the corresponding deprotected glycoside was dried on the vacuum line.

General procedure for coupling reaction with decaborane: $B_{10}H_{14}$ (1.8 equiv.) in dry ACN (5 ml/150 mg) under argon was heated to 60 °C and stirred for 1 h. Meanwhile, the propargylated glycoside (1 equiv.) was dissolved in dry toluene (5 ml/150 mg) and added after the first hour. The reaction mixture was stirred for 15–18 h at 80 °C. The mixture was quenched by the addition of dry methanol (1.8 ml/200 mg starting material) and allowed to stir for 30 min. at 80 °C. The solvent was removed and the crude product was purified by column chromatography (EtOAc:Hexane 1:3), the solvents were removed and the corresponding carboranyl glycoside was dried on the vacuum line.

General procedure for deprotection of benzyl groups: The corresponding protected glucoside was dissolved in EtOAc:MeOH 7:1 (1 ml/10 mg of starting material). Pd/C (10% Pd, 1 weightequiv.) was added and the reaction mixture was stirred in an autoclave under H_2 (3–5 bar) for 4–6 h. The resulting mixture was filtered through celite, washed with EtOAc:MeOH 7:1 (3 x 10 ml) and concentrated under vacuum. The crude product was purified by column chromatography (DCM:MeOH 5:1), the solvents were removed and the product was dried on the vacuum line to give the corresponding deprotected glucoside/glucopyranose.

Substrate specific analytical data

6-*O*-(tert-butyldimethylsilyl)-D-glucopyranose. Synthesised from D-glucose (9.99 g/ 55.5 mmol), according to the general procedure for selective silvlation of the 6-OH group in glucopyranoses. This reaction yielded an off-white powder (10.64 g, 69 %; α:β 58:42). $R_f = 0.61$ (DCM:MeOH 5:1).

¹H NMR of the α-anomer (500.13 MHz; CD₃OD): δ 5.08 (d, 1H, $J_{1,2} = 3.7$ Hz, H-1), 3.85 (dd, 1H, $J_{6a,5} = 2.1$, $J_{6a,6b} = -11.2$ Hz, H-6a), 3.84 (dd, 1H, $J_{6b,5} = 4.6$ Hz, H-6b), 3.75 (ddd, 1H, $J_{5,4} = 9.8$ Hz, H-5), 3.67 (dd, 1H, 1H, $J_{3,4} = 9.1$, $J_{3,2} = 9.6$ Hz, H-3), 3.35 (dd, 1H, H-4), 3.33 (dd, 1H, H-2), 0.90 (s, 9H, 6-OSi(CH₃)₂C(CH₃)₃) and 0.08 and 0.07 (each s, each 3H, 6-OSi(CH₃)₂C(CH₃)₃) ppm. ¹³C NMR of the α-anomer (125.76 MHz; CD₃OD): δ 93.9 (C-1), 74.9 (C-3), 73.8 (C-2), 73.2 (C-5), 71.6 (C-4), 64.1 (C-6), 26.4 (6-OSi(CH₃)₂C(CH₃)₃), 19.3 (6-OSi(CH₃)₂C(CH₃)₃) and -5.0 and -5.1 (6-OSi(CH₃)₂C(CH₃)₃) ppm.

¹H NMR of the β-anomer (500.13 MHz; CD₃OD): δ 4.44 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1), 3.94 (dd, 1H, $J_{6a,5} = 2.0$, $J_{6a,6b} = -11.2$ Hz, H-6a), 3.78 (dd, 1H, $J_{6b,5} = 5.4$ Hz, H-6b), 3.33 (dd, 1H, 1H, $J_{3,4} = 8.9$, $J_{3,2} = 9.8$ Hz, H-3), 3.30 (dd, 1H, $J_{4,5} = 9.4$ Hz, H-4), 3.26 (ddd, 1H, H-5), 3.11 (dd, 1H, H-2), 0.90 (s, 9H, 6-OSi(CH₃)₂C(CH₃)₃) and 0.08 and 0.07 (each s, each 3H, 6-OSi(CH₃)₂C(CH₃)₃) ppm.

¹³C NMR of the β-anomer (125.76 MHz; CD₃OD): δ 98.1 (C-1), 78.2 (C-3, C-5), 76.2 (C-2), 71.5 (C-4), 64.3 (C-6), 26.4 (6-OSi(CH₃)₂C(CH₃)₃), 19.3 (6-OSi(CH₃)₂C(CH₃)₃) and -5.1 (6-OSi(CH₃)₂C(CH₃)₃) ppm.

HRMS: m/z calcd. for C₁₂H₂₆O₆SiNa [M + Na]⁺317.1397; found 317.1385.

1,2,3,4-tetra-*O***-benzyl-6***-O***-(tert-butyldimethylsilyl)**-D-glucopyranose (4). Synthesised from 6-*O*-(tert-butyldimethylsilyl)-D-glucopyranose (0.95 g, 3.2 mmol), NaH (0.90 g, 37.4 mmol) and BnBr (4.90 g, 28.6 mmol) according to the general procedure for alkylation of free hydroxyl groups to give a white solid (1.85 g, 88 %; α : β 31:69). TLC: R_f: 0.39 (EtOAc:Hex 1:8).

¹H NMR of the α -anomer (500.13 MHz; CDCl₃): δ 7.42–7.23 (m, 20H, arom. H), 5.00 and 4.84 (each d, each 1H, J = -10.6 Hz, 3-OCH₂Ph), 4.89 and 4.66 (each d, each 1H, J = -11.0 Hz, 4-OCH₂Ph), 4.83 (d, 1H, $J_{1,2} = 3.6$ Hz, H-1), 4.69 and 4.56 (each d, each 1H, J = -11.9 Hz, 1-OCH₂Ph), 4.66 and 4.58 (each d, each 1H, J = -11.7 Hz, 2-OCH₂Ph), 4.06 (dd,1H, $J_{3,4} = 9.1$, $J_{3,2} = 9.8$ Hz, H-3), 3.78 (dd, 1H, $J_{6a,5} = 4.6$, $J_{6a,6b} = -11.4$ Hz, H-6a), 3.74 (dd, 1H, $J_{6b,5} = 1.7$ Hz, H-6b), 3.71 (ddd, 1H, $J_{5,4} = 10.0$ Hz, H-5), 3.56 (dd, 1H, H-4), 3.52 (dd, 1H, H-2), 0.90 (s, 9H, 6-OSi(CH₃)₂C(CH₃)₃) and 0.06 and 0.05 (each s, each 3H, 6-OSi(CH₃)₂C(CH₃)₃) ppm.

¹³C NMR of the α-anomer (125.76 MHz; CDCl₃): δ 139.0–127.7 (arom. C), 95.2 (C-1), 82.3 (C-3), 80.5 (C-2), 78.0 (C-4), 76.0 (3-OCH₂Ph), 75.2 (4-OCH₂Ph), 73.1 (2-OCH₂Ph), 71.9 (C-5), 68.8 (1-OCH₂Ph), 62.3 (C-6), 26.1 (6-OSi(CH₃)₂C(CH₃)₃), 18.5 (6-OSi(CH₃)₂C(CH₃)₃) and -5.0 and -5.2 (6-OSi(CH₃)₂C(CH₃)₃) ppm.

¹H NMR of the β-anomer (500.13 MHz; CDCl₃): δ 7.42–7.23 (m, 20H, arom. H), 4.97 and 4.73 (each d, each 1H, J = -10.8 Hz, 2-OCH₂Ph), 4.94 and 4.67 (each d, each 1H, J = -11.6 Hz, 1-OCH₂Ph), 4.92 and 4.81 (each d, each 1H, J = -10.8 Hz, 3-OCH₂Ph), 4.86 and 4.69 (each d, each 1H, J = -10.8 Hz, 4-OCH₂Ph), 4.51 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1), 3.90 (dd, 1H, $J_{6a,5} = 1.7$, $J_{6a,6b} = -11.4$ Hz, H-6a), 3.86 (dd, 1H, $J_{6b,5} = 4.4$ Hz, H-6b), 3.65 (dd, 1H, $J_{3,2} = 8.9$, $J_{3,4} = 9.0$ Hz, H-3), 3.63 (dd, 1H, $J_{4,5} = 1.1$

9.5 Hz, H-4), 3.49 (dd, 1H, H-2), 3.30 (ddd, 1H, H-5), 0.93 (s, 9H, 6-OSi(CH₃)₂C(CH₃)₃) and 0.12 and 0.10 (each s, each 3H, 6-OSi(CH₃)₂C(CH₃)₃) ppm.

¹³C NMR of the β-anomer (125.76 MHz; CDCl₃): δ 139.0–127.7 (arom. C), 102.4 (C-1), 84.9 (C-3), 82.7 (C-2), 77.8 (C-4), 76.0 (C-5, 3-OCH₂Ph), 75.2 (4-OCH₂Ph), 75.1 (2-OCH₂Ph), 71.0 (1-OCH₂Ph), 62.4 (C-6), 26.1 (6-OSi(CH₃)₂C(CH₃)₃), 18.5 (6-OSi(CH₃)₂C(CH₃)₃) and –4.8 and –5.2 (6-OSi(CH₃)₂C(CH₃)₃) ppm.

HRMS: m/z calcd. for C₄₀H₅₀O₆SiNa [M + Na]⁺ 677.3275; found 677.3300.

1,2,3,4-tetra-*O***-benzyl-D-glucopyranose.** Synthesised from 1,2,3,4-tetra-*O*-benzyl-6-*O*-(tert-butyldimethylsilyl)-D-glucopyranose (1.73 g, 2.6 mmol) and HF-pyridine (1.6 ml, 17.8 mmol) according to the general procedure for deprotection of silyl protective groups to give a white solid (1.42 g, 99 %; α : β 33:67). TLC: R_f: 0.8 (EtOAc:Hex 1:1).

¹H NMR of the α-anomer (500.13 MHz; CDCl₃): δ 7.41–7.25 (m, 20H, arom. H), 5.01 and 4.84 (each d, each 1H, J = -10.8 Hz, 3-OCH₂Ph), 4.89 and 4.64 (each d, each 1H, J = -11.0 Hz, 4-OCH₂Ph), 4.80 (d, 1H, $J_{1,2} = 3.6$ Hz, H-1), 4.68 and 4.56 (each d, each 1H, J = -11.9 Hz, 2-OCH₂Ph), 4.68 and 4.55 (each d, each 1H, J = -12.4 Hz, 1-OCH₂Ph), 4.06 (dd, 1H, $J_{3,4} = 9.2$, $J_{3,2} = 9.5$ Hz, H-3), 3.71 (ddd, 1H, $J_{5,6a} = 2.7$, $J_{5,6b} = 2.8$, $J_{5,4} = 9.5$ Hz, H-5), 3.70 (ddd, 1H, $J_{6a,6-OH} = 5.7$, $J_{6a,6b} = -11.1$ Hz, H-6a), 3.68 (ddd, 1H, $J_{6a,6-OH} = 7.0$ Hz, H-6b), 3.54 (dd, 1H, H-4), 3.50 (dd, 1H, H-2) and 1.57 (dd, 1H, 6-OH) ppm.

¹³C NMR of the α-anomer (125.76 MHz; CDCl₃): δ 139.0–127.7 (arom. C), 95.7 (C-1), 82.1 (C-3), 80.2 (C-2), 77.6 (C-4), 75.9 (3-OCH₂Ph), 75.2 (4-OCH₂Ph), 73.2 (2-OCH₂Ph), 71.1 (C-5), 69.4 (1-OCH₂Ph) and 62.0 (C-6) ppm.

¹H NMR of the β-anomer (500.13 MHz; CDCl₃): δ 7.41–7.25 (m, 20H, arom. H), 4.95 and 4.73 (each d, each 1H, J = -10.9 Hz, 2-OCH₂Ph), 4.93 and 4.81 (each d, each 1H, J = -10.9 Hz, 3-OCH₂Ph), 4.92 and 4.69 (each d, each 1H, J = -11.9 Hz, 1-OCH₂Ph), 4.86 and 4.64 (each d, each 1H, J = -11.0 Hz, 12

 Hz, 4-OCH₂Ph), 4.57 (d, 1H, $J_{1,2} = 7.9$ Hz, H-1), 3.87 (ddd, 1H, $J_{6a,5} = 2.9$, $J_{6a,6-OH} = 5.8$, $J_{6a,6b} = -11.5$ Hz, H-6a), 3.70 (ddd, 1H, $J_{6b,5} = 4.9$, $J_{6b,6-OH} = 7.7$ Hz, H-6b), 3.67 (dd, 1H, $J_{3,2} = 9.2$, $J_{3,4} = 9.2$ Hz, H-3), 3.57 (dd, 1H, $J_{4,5} = 9.7$ Hz, H-4), 3.49 (dd, 1H, H-2), 3.36 (ddd, 1H, H-5) and 1.84 (dd, 1 H, 6-OH) ppm.

¹³C NMR of the β-anomer (125.76 MHz; CDCl₃): δ 139.0–127.7 (arom. C), 103.0 (C-1), 84.7 (C-3), 82.5 (C-2), 77.7 (C-4), 75.9 (3-OCH₂Ph), 75.2 (C-5, 4-OCH₂Ph), 75.1 (2-OCH₂Ph), 71.8 (1-OCH₂Ph) and 62.2 (C-6) ppm.

HRMS: m/z calcd. for C₃₄H₃₆O₆Na [M + Na]⁺ 563.2410; found 563.2395.

1,2,3,4-tetra-*O***-benzyl-6***-O***-propargyl-D-glucopyranose (5).** Synthesised from 1,2,3,4-tetra-*O*-benzyl-D-glucopyranose (1.42 g, 2.6 mmol, 1.0 equiv.), NaH (0.15 g, 6.0 mmol) and propargyl-bromide (0.56 g, 4.7 mmol) according to the general procedure for alkylation of free hydroxyl groups to give a white solid (1.26 g, 83 %; α : β 31:69).

¹H NMR of the α -anomer (500.13 MHz; CDCl₃): δ 7.42–7.23 (m, 20H, arom. H), 5.00 and 4.84 (each d, each 1H, J = -10.9 Hz, 3-OCH₂Ph), 4.87 and 4.68 (each d, each 1H, J = -11.2 Hz, 4-OCH₂Ph), 4.83 (d, 1H, $J_{1,2} = 3.5$ Hz, H-1), 4.68 and 4.55 (each d, each 1H, J = -12.2 Hz, 1-OCH₂Ph), 4.67 and 4.56 (each d, each 1H, J = -12.1 Hz, 2-OCH₂Ph), 4.20 (dd, 1H, $J_{CH2a,CH} = -2.4$, $J_{CH2a,CH2b} = -16.0$ Hz, 6-OCH_{2a}C=CH), 4.12 (dd, 1H, $J_{CH2b,CH} = -2.4$ Hz, 6-OCH_{2b}C=CH), 4.04 (dd, 1H, $J_{3,4} = 9.0$, $J_{3,2} = 9.7$ Hz, H-3), 3.83 (dd, 1H, $J_{6a,5} = 3.4$, $J_{6a,6b} = -10.0$ Hz, H-6a), 3.81 (ddd, 1H, $J_{5,6b} = 1.6$, $J_{5,4} = 10.3$ Hz, H-5), 3.63 (dd, 1H, H-4), 3.58 (dd, 1H, H-6b), 3.54 (dd, 1H, H-2) and 2.37 (dd, 1H, 6-OCH₂C=CH) ppm.

¹³C NMR of the α-anomer (125.76 MHz; CDCl₃): δ 139.1–127.7 (arom. C), 95.9 (C-1), 82.2 (C-3),
79.9 (C-2), 79.6 (6-OCH₂C≡CH), 77.6 (C-4), 75.8 (3-OCH₂Ph), 75.2 (6-OCH₂C≡CH), 75.1 (4-

OCH₂Ph), 73.1 (2-OCH₂Ph), 70.3 (C-5), 69.4 (1-OCH₂Ph), 68.1 (C-6) and 58.7 (6-OCH₂C≡CH) ppm.

¹H NMR of the β-anomer (500.13 MHz; CDCl₃): δ 7.41–7.25 (m, 20H, arom. H), 4.97 and 4.66 (each d, each 1H, J = -11.9 Hz, 1-OCH₂Ph), 4.95 and 4.72 (each d, each 1H, J = -10.9 Hz, 2-OCH₂Ph), 4.92 and 4.79 (each d, each 1H, J = -11.0 Hz, 3-OCH₂Ph), 4.86 and 4.68 (each d, each 1H, J = -10.8 Hz, 4-OCH₂Ph), 4.51 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1), 4.26 (dd, 1H, $J_{CH2a,CH} = -2.4$, $J_{CH2a,CH2b} = -15.9$ Hz, 6-OCH_{2a}C=CH), 4.20 (dd, 1H, $J_{CH2b,CH} = -2.4$ Hz, 6-OCH_{2b}C=CH), 3.83 (dd, 1H, $J_{6a,5} = 4.5$, $J_{6a,6b} = -10.7$ Hz, H-6a), 3.79 (dd, 1H, $J_{6b,5} = 2.1$ Hz, H-6b), 3.64 (dd, 1H, $J_{3,4} = 9.0$, $J_{3,2} = 9.2$ Hz, H-3), 3.62 (dd, 1H, $J_{4,5} = 9.6$ Hz, H-4), 3.51 (dd, 1H, H-2), 3.47 (ddd, 1H, H-5) and 2.39 (dd, 1H, 6-OCH₂C=CH) ppm.

¹³C NMR of the β-anomer (125.76 MHz; CDCl₃): δ 139.0–127.7 (arom. C), 102.8 (C-1), 84.8 (C-3), 82.4 (C-2), 79.8 (6-OCH₂C=CH), 77.7 (C-4), 75.8 (3-OCH₂Ph), 75.1–74.9 (C-2, 4-OCH₂Ph, 2-OCH₂Ph, 6-OCH₂C=CH), 74.8 (C-5), 71.3 (1-OCH₂Ph), 68.5 (C-6) and 58.8 (6-OCH₂C=CH) ppm. HRMS: m/z calcd. for C₃₇H₃₈O₆Na [M + Na]⁺ 601.2566; found 601.2628.

1,2,3,4-tetra-*O***-benzyl-6***-O***-(o-carboranylmethyl)**-**D-glucopyranose** (6). Synthesised from 1,2,3,4-tetra-*O*-benzyl-6-*O*-propargyl-D-glucopyranose (0.91 g, 1.6 mmol) and B₁₀H₁₄ (0.33 g, 2.7 mmol) according to the general procedure for coupling reaction of decaborane with propargylated glucosides to give a colorless oil (0.61 g, 55.1 %; α :β 25:75). TLC: R_{*j*}: 0.55 (EtOAc:Hex 1:3). ¹H NMR of the α-anomer (500.13 MHz; CDCl₃): δ 7.39–7.23 (m, 20H, arom. H), 5.01 and 4.81 (each d, each 1H, J = -10.6 Hz, 3-OCH₂Ph), 4.90 and 4.55 (each d, each 1H, J = -11.1 Hz, 4-OCH₂Ph), 4.79 (d, 1H, $J_{1,2} = 3.7$ Hz, H-1), 4.68 and 4.56 (each d, each 1H, J = -11.8 Hz, 2-OCH₂Ph), 4.66 and 4.53 (each d, each 1H, J = -12.2 Hz, 1-OCH₂Ph), 4.04 (dd, 1H, $J_{3,4} = 9.1, J_{3,2} = 9.4$ Hz, H-3), 3.87 and 3.79 (each d, each 1H, J = -10.7 Hz, 6-OCH₂-carborane), 3.81 (br s, 1H, carborane-CH), 3.74

 $(ddd, 1H, J_{5,6b} = 1.7, J_{5,6a} = 4.6, J_{5,4} = 10.1 Hz, H-5), 3.63 (dd, 1H, J_{6a,6b} = -11.5 Hz, H-6a), 3.49 (dd, 2H, H-6a), 3.49 (dd,$ 1H, H-2), 3.46 (dd, 1H, H-6b), 3.40 (dd, 1H, H-4) and 2.99–1.50 (br m, 10H, carborane-BH) ppm. ¹³C NMR of the α-anomer (125.76 MHz; CDCl₃): δ 138.7–127.9 (arom. C), 95.6 (C-1), 82.1 (C-3), 80.2 (C-2), 77.5 (C-4), 76.0 (3-OCH₂Ph), 75.1 (4-OCH₂Ph), 73.2 (2-OCH₂Ph), 72.9 (6-OCH₂carborane), 71.0 (C-6, carborane-C), 70.6 (C-5), 69.4 (1-OCH₂Ph) and 57.6 (carborane-CH) ppm. ¹H NMR of the β-anomer (500.13 MHz; CDCl₃): δ 7.39–7.23 (m, 20H, arom. H), 4.96 and 4.73 (each d. each 1H. J = -10.8 Hz. 2-OCH₂Ph). 4.93 and 4.78 (each d. each 1H. J = -10.8 Hz. 3-OCH₂Ph). 4.88 and 4.66 (each d, each 1H, J = -11.9 Hz, 1-OCH₂Ph), 4.87 and 4.55 (each d, each 1H, J = -11.2Hz, 4-OCH₂Ph), 4.49 (d, 1H, $J_{1,2} = 7.9$ Hz, H-1), 3.93 and 3.87 (each d, each 1H, J = -10.7 Hz, 6-OCH₂-carborane), 3.91 (br s, 1H, carborane-CH), 3.67 (dd, 1H, $J_{6a.5} = 4.8$, $J_{6a.6b} = -11.4$ Hz, H-6a), 3.64 (dd, 1H, $J_{6b,5} = 1.9$ Hz, H-6b), 3.63 (dd, 1H, $J_{3,4} = 9.0$, $J_{3,2} = 9.2$ Hz, H-3), 3.47 (dd, 1H, H-2), 3.44 (dd, 1H, *J*_{4.5} = 9.9 Hz, H-4), 3.36 (ddd, 1H, H-5) and 2.99–1.50 (br m, 10H, carborane-BH) ppm. ¹³C NMR of the β-anomer (125.76 MHz; CDCl₃): δ 138.7–127.9 (arom. C), 102.8 (C-1), 84.7 (C-3), 82.4 (C-2), 77.4 (C-4), 76.0 (3-OCH₂Ph), 75.1 (2-OCH₂Ph, 4-OCH₂Ph), 74.8 (C-5), 72.9 (6-OCH₂carborane), 71.5 (1-OCH₂Ph), 71.0 (C-6, carborane-C) and 57.7 (carborane-CH) ppm. ¹¹B NMR (160.46 MHz; CDCl₃): δ –2.56, –4.38, –8.64, –11.24 and –12.91 ppm. HRMS: m/z calcd. for C₃₇H₄₈B₁₀O₆Na [M + Na]⁺721.4258; found 721.4327.

6-*O*-(o-carboranylmethyl)-D-glucopyranose (1). Synthesised from 1,2,3,4-tetra-*O*-benzyl-6-*O*-(o-carboranylmethyl)-D-glucopyranose (0.11 g, 0.02 mmol), and Pd/C (0.17 g, 0.02 mmol) according to the general procedure for hydrogenolysis to give a colorless oil (0.04 g, 79 %; α :β 60:40). TLC: R_{f} : 0.56 (EtOAc:MeOH 5:1).

¹H NMR of the α -anomer (500.13 MHz; CD₃OD): δ 5.10 (d, 1H, $J_{1,2}$ = 3.7 Hz, H-1), 4.59 (br s, 1H, carborane-CH), 4.04 and 4.02 (each d, each 1H, J = -10.8 Hz, 6-OCH₂-carborane), 3.86 (ddd, 1H, $J_{5,6b}$ = 1.8, $J_{5,6a}$ = 4.9, $J_{5,4}$ = 10.1 Hz, H-5), 3.75 (dd, 1H, $J_{6a,6b}$ = -11.3 Hz, H-6a), 3.73 (dd, 1H, H-15)

6b), 3.66 (dd, 1H, *J*_{3,4} = 9.0, *J*_{3,2} = 9.6 Hz, H-3), 3.35(dd, 1H, H-2), 3.29 (dd, 1H, H-4) and 3.00–1.50 (br m, 10H, carborane-B**H**) ppm.

¹³C NMR of the α-anomer (125.76 MHz; CD₃OD): δ 93.9 (C-1), 75.2 (carborane-C), 74.8 (C-3), 73.9 (6-OCH₂-carborane), 73.7 (C-2), 72.5 (C-6), 72.2 (C-5), 71.6 (C-4) and 60.5 (carborane-CH) ppm. ¹H NMR of the β-anomer (500.13 MHz; CD₃OD): δ 4.63 (br s, 1H, carborane-CH), 4.46 (d, 1H, $J_{1,2}$ = 7.8 Hz, H-1), 4.05 and 4.03 (each d, each 1H, J= –10.8 Hz, 6-OCH₂-carborane), 3.79 (dd, 1H, $J_{6a,5}$ = 2.0, $J_{6a,6b}$ = –11.3 Hz, H-6a), 3.72 (dd, 1H, $J_{6b,5}$ = 5.2 Hz,H-6b), 3.37 (ddd, 1H, $J_{5,4}$ = 10.3 Hz, H-5), 3.34 (dd, 1H, $J_{3,2}$ = 9.0, $J_{3,4}$ = 9.3 Hz, H-3), 3.30 (dd, 1H, H-4), 3.12 (dd, 1H, H-2) and 3.00–1.50 (br m, 10H, carborane-BH) ppm.

¹³C NMR of the β-anomer (125.76 MHz; CD₃OD): δ 98.2 (C-1), 78.0 (C-3), 76.9 (C-5), 76.2 (C-2), 75.2 (carborane-C), 73.9 (6-OCH₂-carborane), 72.2 (C-6), 71.3 (C-4) and 60.6 (carborane-CH) ppm. ¹¹B NMR (160.46 MHz; CD₃OD): δ –2.09, –4.01, –8.31, –10.48 and –12.17 ppm. HRMS: m/z calcd. for C₉H₂₄B₁₀O₆Na [M + Na]⁺ 361.2401; found 361.2382.

Methyl 6-*O*-tertbutyldimethylsilyl- α -D-glucopyranoside. Synthesised from methyl- α -D-glucopyranoside (9.91 g, 51 mmol), according to the general procedure for selective silvlation of the 6-OH group in glucopyranosides. This reaction yielded a white solid (12.61 g, 80 %). $R_f = 0.52$ (DCM:MeOH 7:1).

¹H NMR (500.13 MHz; CDCl₃): δ 4.74 (d, 1H, $J_{1,2} = 3.7$ Hz, H-1), 3.88 (dd, 1H, $J_{6a,5} = 5.0$, $J_{6a,6b} = -10.8$ Hz, H-6a), 3.83 (dd, 1H, $J_{6b,5} = 5.0$ Hz, H-6b), 3.74 (dd, 1H, $J_{3,2} = J_{3.4} = 8.9$, 9.6 Hz, H-3), 3.60 (ddd, 1H, $J_{5,4} = 9.8$ Hz, H-5), 3.52 (dd, 1H, H-2), 3.52 (dd, 1H, H-4), 3.42 (s, 3H, 1-OCH₃), 0.91 (s, 9H, 6-OSi(CH₃)₂C(CH₃)₃) and 0.10 (s, 6H, 6-OSi(CH₃)₂C(CH₃)₃) ppm.

¹³C NMR (125.76 MHz; CDCl₃): δ 99.3 (C-1), 74.8 (C-3), 72.4–72.3 (C-2, C-4), 70.6 (C-5), 64.3 (C-6), 55.4 (1-OCH₃), 26.0 (6-OSi(CH₃)₂C(CH₃)₃), 18.4 (6-OSi(CH₃)₂C(CH₃)₃) and -5.3 (6-OSi(CH₃)₂C(CH₃)₃) ppm.

HRMS: m/z calcd. for C₁₃H₂₈O₆SiNa [M + Na]⁺ 331.1553; found 331.1553.

Methyl 2,3,4-tri-*O*-benzyl-6-*O*-tertbutyldimethylsilyl- α -D-glucopyranoside (7). Synthesised from methyl 6-*O*-tertbutyldimethylsilyl- α -D-glucopyranoside (0.60 g, 1.93 mmol), according to the general procedure for the alkylation of free hydroxyl groups. This reaction yielded a white solid (0.70 g, 78 %). R_f = 0.32 (EtOAc:Hexane 1:8).

¹H NMR (500.13 MHz; CDCl₃): δ 7.37–7.26 (m, 15H, arom. H), 4.97 and 4.82 (each d, each 1H, J = -10.7 Hz, 3-OCH₂Ph), 4.88 and 4.64 (each d, each 1H, J = -10.9 Hz, 4-OCH₂Ph), 4.79 and 4.68 (each d, each 1H, J = -12.1 Hz, 2-OCH₂Ph), 4.61 (d, 1H, $J_{1,2} = 3.6$ Hz, H-1), 3.99 (dd, 1H, $J_{3,4} = 9.0$, $J_{3,2} = 9.6$ Hz, H-3), 3.78 (m, 2H, H-6a and H-6b), 3.61 (ddd, 1H, $J_{5,6a} = 3.1$, $J_{5,6b} = 3.1$, $J_{5,4} = 10.0$ Hz, H-5), 3.53 (dd, 1H, H-4), 3.50 (dd, 1H, H-2) and 3.36 (s, 3H, 1-OCH₃), 0.88 (s, 9H, 6-OSi(CH₃)₂C(CH₃)₃) and 0.04 and 0.03 (each s, each 3H, 6-OSi(CH₃)₂C(CH₃)₃) ppm. ¹³C NMR (125.76 MHz; CDCl₃): δ 139.3–127.6 (arom. C), 98.0 (C-1), 82.3 (C-3), 80.4 (C-2), 77.9 (C-4), 76.0 (3-OCH₂Ph), 75.1 (4-OCH₂Ph), 73.5 (2-OCH₂Ph), 71.6 (C-5), 62.4 (C-6), 55.0 (1-O-CH₃), 26.1 (6-OSi(CH₃)₂C(CH₃)₃) and -5.1 (6-OSi(CH₃)₂C(CH₃)₃)

ppm.

HRMS: m/z calcd. for C₃₄H₄₆O₆SiNa [M + Na]⁺ 601.2962; found 601.2983.

Methyl 2,3,4-tri-*O*-benzyl- α -D-glucopyranoside. Synthesised from methyl 2,3,4-tri-*O*-benzyl-6-*O*-tertbutyldimethylsilyl- α -D-glucopyranoside (2.6 g, 4.49 mmol), according to the general procedure for deprotection of silyl protective groups. This reaction yielded a white solid (1.70 g, 82 %). R_f = 0.60 (EtOAc:Hexane 1:1).

¹H NMR (500.13 MHz; CDCl₃): δ 7.37–7.28 (m, 15H, arom. H), 4.99 and 4.84 (each d, each 1H, J = -10.9 Hz, 3-OCH₂Ph), 4.88 and 4.64 (each d, each 1H, J = -11.0 Hz, 4-OCH₂Ph), 4.80 and 4.67 (each d, each 1H, J = -12.1 Hz, 2-OCH₂Ph), 4.56 (d, 1H, $J_{1,2} = 3.6$ Hz, H-1), 4.00 (dd, 1H, $J_{3,4} = 8.9$,

 $J_{3,2} = 9.6$ Hz, H-3), 3.76 (ddd, 1H, $J_{6a,5} = 2.7$, $J_{6a,6-OH} = 5.3$, $J_{6a,6b} = -11.9$ Hz, H-6a), 3.69 (ddd, 1H, $J_{6b,5} = 4.1$, $J_{6b,6-OH} = 7.6$ Hz, H-6b), 3.65 (ddd, 1H, $J_{5,4} = 9.9$ Hz, H-5), 3.52 (dd, 1H, H-4), 3.50 (dd, 1H, H-2), 3.37 (s, 3H, 1-OCH₃) and 1.62 (dd, 1H, 6-OH) ppm.

¹³C NMR (125.76 MHz; CDCl₃): δ 139.7–127.7 (arom. C), 98.3 (C-1), 82.1 (C-3), 80.1 (C-2), 77.5 (C-4), 75.9 (3-OCH₂Ph), 75.2 (4-OCH₂Ph), 73.6 (2-OCH₂Ph), 70.8 (C-5), 62.0 (C-6) and 55.3 (1-OCH₃) ppm.

HRMS: m/z calcd. for C₂₈H₃₂O₆Na [M + Na]⁺ 487.2097; found 487.2084.

Methyl 2,3,4-tri-*O*-benzyl-6-*O*-propargyl- α -D-glucopyranoside (8). Synthesised from methyl 2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (0.31 g, 0.67 mmol), according to the general procedure for the alkylation of free hydroxyl groups. This reaction yielded a yellow oil (0.30 g, 89 %). R_f = 0.61 (EtOAc:Hexane 1:2).

¹H NMR (500.13 MHz; CDCl₃): δ 7.37–7.26 (m, 15H, arom. H), 4.98 and 4.83 (each d, each 1H, J = -10.9 Hz, 3-OCH₂Ph), 4.87 and 4.65 (each d, each 1H, J = -11.4 Hz, 4-OCH₂Ph), 4.79 and 4.68 (each d, each 1H, J = -11.7 Hz, 2-OCH₂Ph), 4.60 (d, 1H, $J_{1,2} = 3.6$ Hz, H-1), 4.19 (dd, 1H, $J_{CH2a,CH} = -2.4$, $J_{CH2a,CH2b} = -16.0$ Hz, 6-OCH_{2a}C=CH), 4.13 (dd, 1H, $J_{CH2a,CH} = -2.4$ Hz, 6-OCH_{2b}C=CH), 3.98 (dd, 1H, $J_{3,4} = 9.0$, $J_{3,2} = 9.7$ Hz, H-3), 3.84 (dd, 1H, $J_{6a,5} = 3.5$, $J_{6a,6b} = -10.4$ Hz, H-6a), 3.76 (dd, 1H, $J_{5,6b} = 2.1$, $J_{5,4} = 10.1$ Hz, H-5), 3.66 (dd, 1H, H-6b), 3.61 (dd, 1H, H-4), 3.54 (dd, 1H, H-2), 3.37 (s, 3H, 1-OCH₃) and 2.37 (dd, 1H, 6-OCH₂C=CH) ppm.

¹³C NMR (125.76 MHz; CDCl₃): δ 139.6–127.7 (arom. C), 98.5 (C-1), 82.2 (C-3), 79.9 (C-2), 79.6 (6-OCH₂C≡CH), 77.6 (C-4), 75.9 (3-OCH₂Ph), 75.2 (4-OCH₂Ph), 75.1 (6-OCH₂C≡CH), 73.6 (2-OCH₂Ph), 70.0 (C-5), 68.2 (C-6), 58.7 (6-OCH₂C≡CH) and 55.4 (1-OCH₃) ppm.

HRMS: m/z calcd. for C₃₁H₃₄O₆Na [M + Na]⁺ 525.2253; found 525.2258.

Methyl 2,3,4-tri-*O*-benzyl-6-*O*-(o-carboranylmethyl)- α -D-glucopyranoside (9). Synthesised from methyl 2,3,4-tri-*O*-benzyl-6-*O*-propargyl- α -D-glucopyranoside (0.37 g, 0.73 mmol), according to the general procedure for coupling with decaborane. This reaction yielded a white solid (0.27 g, 5 3%). $R_f = 0.33$ (EtOAc:Hexane 1:3).

¹H NMR (500.13 MHz; CDCl₃): δ 7.38–7.25 (m, 15H, arom. H), 4.99 and 4.80 (each d, each 1H, J = -10.8 Hz, 3-OCH₂Ph), 4.90 and 4.55 (each d, each 1H, J = -11.2 Hz, 4-OCH₂Ph), 4.81 and 4.67 (each d, each 1H, J = -12.0 Hz, 2-OCH₂Ph), 4.55 (d, 1H, $J_{1,2} = 3.5$ Hz, H-1), 3.97 (dd, 1H, $J_{3,4} = 8.8$, $J_{3,2} = 9.6$ Hz, H-3), 3.89 and 3.80 (each d, each 1H, J = -10.5 Hz, 6-OCH₂-carborane), 3.81 (br s, carborane-CH), 3.67 (ddd, 1H, $J_{5,6b} = 1.8$, $J_{5,6a} = 4.4$, $J_{5,4} = 9.7$, Hz, H-5), 3.65 (dd, 1H, $J_{6a,6b} = -10.9$ Hz, H-6a), 3.55 (dd, 1H, H-6b), 3.48 (dd, 1H, H-2), 3.39 (dd, 1H, H-4), 3.35 (s, 3H, 1-OCH₃) and 2.62–1.61 (br m, 10H, carborane-BH) ppm.

¹³C NMR (125.76 MHz; CDCl₃): δ 139.8–127.8 (arom. C), 98.2 (C-1), 82.1 (C-3), 80.1 (C-2), 77.2 (C-4), 76.1 (3-OCH₂Ph), 75.1 (4-OCH₂Ph), 73.6 (2-OCH₂Ph), 72.9 (carborane-C), 71.0 (C-6), 70.3 (C-5), 60.5 (6-OCH₂-carborane), 57.6 (carborane-CH) and 55.4 (1-OCH₃) ppm.

¹¹B NMR (160.46 MHz; CDCl₃): δ –2.74, –4.74, –8.94, –11.52 and –13.06 ppm.

HRMS: m/z calcd. for C₃₁H₄₄B₁₀O₆Na [M + Na]+ 645.3966; found 645.3975.

Methyl 6-*O*-(o-carboranylmethyl)- α -D-glucopyranoside (2). Synthesised from methyl 2,3,4-tri-*O*-benzyl-6-*O*-(o-carboranylmethyl)- α -D-glucopyranoside (0.15 g, 0.25 mmol), according to the general procedure for the deprotection of benzyl groups. This reaction yielded a white solid (0.06 g, 72 %). $R_f = 0.47$ (DCM:MeOH 7:1).

¹H NMR (500.13 MHz; CD₃OD): δ 4.66 (d, 1H, $J_{1,2}$ = 3.8 Hz, H-1), 4.57 (br s, 1H, carborane-CH), 4.04 and 4.01 (each d, each 1H, J = -11.0 Hz, 6-OCH₂-carborane), 3.76 (dd, 1H, $J_{6a,5}$ = 1.8, $J_{6a,6b}$ = -11.3 Hz, H-6a), 3.71 (dd, 1H, $J_{6b,5}$ = 5.3 Hz, H-6b), 3.60 (ddd, 1H, $J_{5,4}$ = 9.7 Hz, H-5), 3.59 (dd, 1H,

*J*_{3,4} = 9.2, *J*_{3,2} = 9.7 Hz, H-3), 3.40 (s, 3H, 1-OC**H**₃), 3.37 (d, 1H, H-2), 3.26 (d, 1H, H-4) and 2.56–1.59 (br m, 10H, carborane-B**H**) ppm.

¹³C NMR (125.76 MHz; CD₃OD): δ 101.3 (C-1), 75.2 (carborane-C), 75.0 (C-3), 74.0 (6-OCH₂carborane), 73.5 (C-2), 72.7 (C-5), 72.3 (C-6), 71.6 (C-4), 60.7 (carborane-CH) and 55.6 (1-OCH₃) ppm.

¹¹B NMR (160.46 MHz; CDCl₃): δ –1.94, –3.92, –8.30, –10.44 and –12.05 ppm.

HRMS: m/z calcd. for C₁₀H₂₆B₁₀O₆Na [M + Na]⁺ 375.2558; found 375.2519.

Methyl 6-*O*-tertbutyldimethylsilyl-β-D-glucopyranoside. Synthesised from methyl β-Dglucopyranoside (0.50 g, 2.59 mmol), according to the general procedure for selective silylation of the 6-OH group in glucopyranosides. This reaction yielded a white solid (0.66 g, 83 %). $R_f = 0.48$ (DCM:MeOH 7:1).

¹H NMR (500.13 MHz; CD₃OD): δ 4.17 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1), 3.99 (dd, 1H, $J_{6a,5} = 2.1$, $J_{6a,6b} = -11.4$ Hz, H-6a), 3.83 (dd, 1H, $J_{6b,5} = 5.3$ Hz, H-6b), 3.53 (s, 3H, 1-OCH₃), 3.36 (dd, 1H, $J_{3,2} = 9.0$, $J_{3,4} = 9.2$ Hz, H-3), 3.33 (dd, 1H, $J_{4,5} = 9.7$ Hz, H-4), 3.27 (ddd, 1H, H-5), 3.17 (dd, 1H, H-2), 0.90 (s, 9H, 6-OSi(CH₃)₂C(CH₃)₃) and 0.09 (s, 6H, 6- OSi(CH₃)₂C(CH₃)₃) ppm. ¹³C NMR (125.76 MHz; CD₃OD): δ 105.3 (C-1), 78.1 (C-3, C-5), 75.0 (C-2), 71.4 (C-4), 64.1 (C-6), 57.2 (1-OCH₃), 26.4 (6-OSi(CH₂)₂CH₃), 19.3 (6-OSi(CH₂)₂CH₃), -5.0 and -5.1 (each Si(CH₃)₂) (each 6-OSi(CH₃)₂C(CH₃)₃) ppm.

HRMS: m/z calcd. for C₁₃H₂₈O₆SiNa [M + Na]⁺ 331.1553; found 331.1531.

Methyl 2,3,4-tri-*O*-benzyl-6-*O*-tertbutyldimethylsilyl-β-D-glucopyranoside (10). Synthesised from methyl 6-*O*-tertbutyldimethylsilyl-β-D-glucopyranoside (3.05 g, 9.89 mmol), according to the general procedure for the alkylation of free hydroxyl groups. This reaction yielded a white solid (4.62 g, 80 %). R_f = 0.33 (EtOAc:Hexane 1:8).

¹H NMR (500.13 MHz; CDCl₃): δ 7.38–7.27 (m, 15H, arom. H), 4.92 and 4.71 (each d, each 1H, J = -11.0 Hz, 2-OCH₂Ph), 4.91 and 4.81 (each d, each 1H, J = -10.8 Hz, 3-OCH₂Ph), 4.85 and 4.68 (each d, each 1H, J = -10.9 Hz, 4-OCH₂Ph), 4.29 (d, 1H, $J_{1,2} = 7.7$ Hz, H-1), 3.88 (dd, 1H, $J_{6a,5} = 1.7$, $J_{6a,6b} = -11.5$ Hz, H-6a), 3.83 (dd, 1H, $J_{6b,5} = 4.3$ Hz, H-6b), 3.64 (dd, 1H, $J_{3,4} = 9.1$, $J_{3,2} = 9.2$ Hz, H-3), 3.59 (dd, 1H, $J_{4,5} = 9.7$ Hz, H-4), 3.54 (s, 3H, 1-OCH₃), 3.38 (dd, 1H, H-2), 3.28 (ddd, 1H, H-5), 0.90 (s, 9H, 6-OSi(CH₃)₂C(CH₃)₃) and 0.08 and 0.07 (each s, each 3H, 6-OSi(CH₃)₂C(CH₃)₃) ppm.

¹³C NMR (125.76 MHz; CDCl₃): δ 139.6–127.7 (arom. C), 104.6 (C-1), 84.8 (C-3), 82.7 (C-2), 77.8 (C-4), 75.9 (3-OCH₂Ph), 75.9 (C-5), 75.2 (4-OCH₂Ph), 74.9 (2-OCH₂Ph), 62.4 (C-6), 56.8 (1-OCH₃), 26.1 (6-OSi(CH₃)₂C(CH₃)₃), 18.5 (6-OSi(CH₃)₂C(CH₃)₃), -4.9 and -5.1 (6-OSi(CH₃)₂C(CH₃)₃) ppm.

HRMS: m/z calcd. for C₃₄H₄₆O₆SiNa [M + Na]⁺ 601.2962; found 601.2964.

Methyl 2,3,4-tri-*O*-benzyl-β-D-glucopyranoside. Synthesised from methyl 2,3,4-tri-*O*-benzyl-6-*O*-tertbutyldimethylsilyl-β-D-glucopyranoside (2.94 g, 5.08 mmol), according to the general procedure for deprotection of silyl protective groups. This reaction yielded a white solid (2.09 g, 89 %). R_f = 0.65 (EtOAc:Hexane 1:1).

¹H NMR (500.13 MHz; CDCl₃): δ 7.38–7.27 (m, 15H, arom. H), 4.93 and 4.81 (each d, each 1H, J = -10.9 Hz, 3-OCH₂Ph), 4.91 and 4.71 (each d, each 1H, J = -11.0 Hz, 2-OCH₂Ph), 4.87 and 4.64 (each d, each 1H, J = -10.9 Hz, 4-OCH₂Ph), 4.36 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1), 3.88 (ddd, 1H, $J_{6a,5} = 2.8$, $J_{6a,6-OH} = 5.5$, $J_{6a,6b} = -12.0$ Hz, H-6a), 3.73 (ddd, 1H, $J_{6b,5} = 4.5$, $J_{6b,6-OH} = 7.7$ Hz, H-6b), 3.67 (dd, 1H, $J_{3,4} = 9.0$, $J_{3,2} = 9.2$ Hz, H-3), 3.57 (dd, 1H, $J_{4,5} = 9.8$ Hz, H-4), 3.57 (s, 3H, 1-OCH₃), 3.40 (dd, 1H, H-2), 3.37 (ddd, 1H, H-5) and 1.88 (dd, 1H, 6-OH) ppm.

¹³C NMR (125.76 MHz; CDCl₃): δ 138.7–127.1 (arom. C), 105.0 (C-1), 84.6 (C-3), 82.5 (C-2), 77.6 (C-4), 75.8 (3-OCH₂Ph), 75.3 (C-5), 75.1 (4-OCH₂Ph), 75.0 (2-OCH₂Ph), 62.2 (C-6) and 57.5 (1-OCH₃) ppm.

HRMS: m/z calcd. for C₂₈H₃₂O₆Na [M + Na]⁺ 487.2097; found 487.2089.

Methyl 2,3,4-tri-*O*-benzyl-6-*O*-propargyl-β-D-glucopyranoside (11). Synthesised from methyl 2,3,4-tri-*O*-benzyl-β-D-glucopyranoside (1.42 g, 3.02 mmol), according to the general procedure for the alkylation of free hydroxyl groups. This reaction yielded a yellow oil (1.44 g, 95 %). R_f = 0.84 (EtOAc:Hexane 1:1).

¹H NMR (500.13 MHz; CDCl₃): δ 7.35–7.26 (m, 15H, arom. H), 4.92 and 4.80 (each d, each 1H, J = -11.0 Hz, 3-OCH₂Ph), 4.91 and 4.70 (each d, each 1H, J = -11.0 Hz, 2-OCH₂Ph), 4.85 and 4.68 (each d, each 1H, J = -10.8 Hz, 4-OCH₂Ph), 4.30 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1), 4.25 (dd, 1H, $J_{CH2a,CH} = -2.4$, $J_{CH2a,CH2b} = -15.9$ Hz, 6-OCH_{2a}C=CH), 3.64 (dd, 1H, $J_{CHb,CH} = -2.4$ Hz, 6-OCH_{2b}C=CH), 3.83 (dd, 1H, $J_{6a,5} = 4.4$, $J_{6a,6b} = -10.7$ Hz, H-6a), 3.78 (dd, 1H, $J_{6b,5} = 2.0$ Hz, H-6b), 3.64 (dd, 1H, $J_{3,2} = 9.1$, $J_{3,4} = 9.1$ Hz, H-3), 3.61 (dd, 1H, $J_{4,5} = 10.0$ Hz, H-4), 3.57 (s, 3H, 1-OCH₃), 3.46 (ddd, 1H, H-5), 3.42 (dd, 1H, H-2) and 2.38 (dd, 1H, 6-OCH₂C=CH) ppm.

¹³C NMR (125.76 MHz; CDCl₃): δ 128.6–127.7 (arom. C), 104.9 (C-1), 84.7 (C-3), 82.4 (C-2), 79.8 (6-OCH₂C≡CH), 77.7 (C-4), 77.8 (3-OCH₂Ph), 76.4 (6-OCH₂C≡CH), 75.1 (4-OCH₂Ph), 74.8 (2-OCH₂Ph), 74.7 (C-5), 68.5 (C-6), 58.8 (6-OCH₂C≡CH) and 57.3 (1-OCH₃) ppm.

HRMS: m/z calcd. for C₃₁H₃₄O₆Na [M + Na]⁺ 525.2253; found 525.2252.

Methyl 2,3,4-tri-*O*-benzyl-6-*O*-(o-carboranylmethyl)-β-D-glucopyranoside (12). Synthesised from methyl 2,3,4-tri-*O*-benzyl-6-*O*-propargyl-β-D-glucopyranoside (1.20 g, 2.38 mmol), according to the general procedure for coupling with decaborane. This reaction yielded a white solid (0.98 g, 66 %). R_f = 0.26 (EtOAc:Hexane 1:4).

¹H NMR (500.13 MHz; CDCl₃): δ 7.35–7.23 (m, 15H, arom. H), 4.93 and 4.78 (each d, each 1H, J = -10.8 Hz, 3-OCH₂Ph), 4.91 and 4.71 (each d, each 1H, J = -11.1 Hz, 2-OCH₂Ph), 4.87 and 4.54 (each d, each 1H, J = -11.1 Hz, 4-OCH₂Ph), 4.28 (d, 1H, $J_{1,2} = 7.1$ Hz, H-1), 3.94 (br s, carborane-CH), 3.94 and 3.89 (each d, each 1H, J = -10.5 Hz, 6-OCH₂-carborane), 3.66 (dd, 1H, $J_{6a,5} = 2.3$, $J_{6a,6b} = -10.5$ Hz, H-6a), 3.65 (dd, 1H, $J_{6b,5} = 4.4$ Hz, H-6b), 3.63 (dd, 1H, $J_{3,4} = 8.8$, $J_{3,2} = 9.3$ Hz, H-3), 3.54 (s, 3H, 1-OCH₃), 3.41 (dd, 1H, $J_{4,5} = 10.0$ Hz , H-4), 3.38 (dd, 1H, H-2), 3.37 (ddd, 1H, H-5) and 2.64–1.77 (br m, 10H, carborane-BH) ppm.

¹³C NMR (125.76 MHz; CDCl₃): δ 138.7–127.9 (arom. C), 104.9 (C-1), 84.6 (C-3), 82.4 (C-2), 77.4 (C-4), 75.9 (3-OCH₂Ph), 75.1 (4-OCH₂Ph), 75.0 (2-OCH₂Ph), 74.7 (C-5), 72.9 (6-OCH₂-carborane and carborane-C), 71.1 (C-6), 57.7 (carborane-CH) and 57.3 (1-OCH₃) ppm.

¹¹B NMR (160.46 MHz; CDCl₃): δ –2.83, –4.62, –8.89, –11.58 and –13.09 ppm.

HRMS: m/z calcd. for C₃₁H₄₄B₁₀O₆Na [M + Na]⁺ 645.3966; found 645.4025.

Methyl 6-*O*-(o-carboranylmethyl)-β-D-glucopyranoside (3). Synthesised from methyl 2,3,4-tri-*O*-benzyl-6-*O*-(o-carboranylmethyl)-β-D-glucopyranoside (0.15 g, 0.25 mmol), according to the general procedure for the deprotection of benzyl groups. This reaction yielded a white solid (0.068 g, 81 %). R_f = 0.61 (DCM:MeOH 5:1).

¹H NMR (500.13 MHz; CD₃OD): δ 4.63 (br s, 1H, carborane-CH), 4.17 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1), 4.06 (each d, each 1H, J = -11.1 Hz, 6-OCH₂-carborane), 3.84 (dd, 1H, $J_{6a,5} = 2.1$, $J_{6a,6b} = -11.3$ Hz, H-6a), 3.73 (dd, 1H, $J_{6b,5} = 5.2$ Hz, H-6b), 3.53 (s, 3H, 1-OCH₃), 3.38 (ddd, 1H, $J_{5,4} = 10.0$ Hz, H-5), 3.35 (dd, 1H, $J_{3,2} = 9.3$, $J_{3,4} = 9.3$ Hz, H-3), 3.30 (dd, 1H, H-4), 3.16 (dd, 1H, H-2) and 2.54–1.54 (br m, 10H, carborane-BH) ppm.

¹³C NMR (125.76 MHz; CD₃OD): δ 105.4 (C-1), 77.8 (C-3), 76.9 (C-5), 75.2 (carborane-C), 74.9 (C-2), 73.9 (6-OCH₂-carborane), 72.2 (C-6), 71.2 (C-4), 60.5 (carborane-CH) and 57.4 (1-OCH₃) ppm.

¹¹B NMR (160.46 MHz; CDCl₃): δ –2.06, –3.97, –8.30, –10.50 and –12.08 ppm. HRMS: *m/z* calcd. for C₁₀H₂₆B₁₀O₆Na [M + Na]⁺ 375.2558; found 375.2557.

2.2 Molecular modelling

The initial geometries of the ligands were optimized to a local minimum at DFT level, using the dispersion-corrected hybrid Tao-Perdew-Scuseria-Staroverov functional TPSSh-D3(BJ),^{26–28} with the doubly polarized triple-zeta basis set def2-TZVPP.²⁹ The structures of the different ligands were aligned so that geometries would be as similar as possible. Partial atomic charges were computed using the restrained electrostatic potential (RESP) protocol.³⁰ For the RESP charge calculation, the molecule was divided into two parts, with one part consisting of the carborane and a linking carbon, and the other part comprising the sugar. Partial charges of hydrogens bonded to the same carbon were constrained to be equal. The geometry optimizations were performed with Turbomole 7.3,^{31,32} and the RESP calculations with NWChem 6.8.³³ Non-covalent interactions (NCI)³⁴ between the ligands and protein were computed using the promolecular approach of NCIPLOT.³⁵

Molecular docking studies were performed using AutoDock 4.2.6.^{36,37} All rotatable bonds in the carborane part were set to nonrotatable (inactive). For docking, the number of torsional degrees of freedom for the carboranes was set to 8 (torsdof 8). The docking studies were performed using the XylE inward-open 4QIQ and outward-open 6N3I PDB structures. The XylE protein structures were mutated using PyMOL, changing Gln-415 to Asn-415. The most probable rotamer, that is, the one with least clashes with surrounding amino acids, as suggested by PyMOL was used. Each protein was prepared by removing the ligand and other superfluous small molecules (Zn for 4QIQ), adding hydrogens, merging them and then computing Gasteiger partial charges. For all proteins, a grid of size 46 x 56 x 60 was used, with a grid spacing value of 0.375. The grid center was in the middle of the protein cavity, for the grid box to cover the binding site. During docking, the protein was kept

rigid and only ligand torsional angles changed. For each ligand, $6000 (3 \times 2000)$ independent search runs, each with max 2.5 million energy evaluations and population size of 150 with max 27000 generations, were performed using the default settings of the Lamarckian genetic algorithm (LGA), that is, a mutation rate of 0.02 and crossover rate of 0.8, with one top individual surviving to the next generation. Conformations were clustered (ranked) with a cluster RMS 2.0 Å.

Parameters for boron, missing from the standard distribution of Autodock, were added to the parameter file: R 2.285, R_{ii} 4.57, epsilon 0.179, vol 49.9744; other parameters were set to their corresponding carbon values. R and epsilon were taken from Oda. et al.,³⁸ as reproduced by Couto et al.,³⁹ and were used to calculate R_{ii} and vol. The complete parameter definition was thus: atom par B 4.57 0.179 49.9744 -0.00143 0.0 0.0 0 -1 -1 0 # Boron for Carborane

2.3. Cytotoxicity studies

The CellTiter-Glo® luminescent cell viability assay was purchased from Promega Corporation (Madison, WI, USA). PierceTM BCA Protein Assay Kit was obtained from Thermo Fisher Scientific (Waltham, MA, USA). Human CAL 27 squamous cell carcinoma was acquired from American Type Culture Collection (Manassas, VA, USA). The cell culturing flasks and 96-well plates were purchased from Corning (Corning, NY, USA). Dulbecco's Modified Eagle's Medium (DMEM), Dulbecco's phosphate buffer saline (10×DPBS), fetal bovine serum (FBS), and Penicillin-Streptomycin (10,000 U/ml) were obtained from Gibco (Life Technologies, Carlsbad, CA, USA).

The *in vitro* cell cytotoxicity was carried out using a commercial CellTiter-Glo® luminescent cell viability assay. The human epithelial CAL 27 squamous carcinoma cell line was used as a head-and-neck cancer cell model in this experiment. The cells were plated on a 96-well plate at 15,000 cells per well in 100 µl DMEM supplemented with 10% FBS and 1% Penicillin-Streptomycin, and cells

were allowed to attach overnight. The medium was removed and replaced with 100 μ l of the glucoconjugates **1**, **2**, **3** or sodium borocaptate (**BSH**) solution in complete cell culture medium at concentrations of 5 μ M, 25 μ M, 50 μ M, 125 μ M and 250 μ M. Fresh medium and 1% (v/v) Triton X-100 were used as positive and negative controls of cell viability, respectively. The incubation time points of the compounds were set at 6 h and 24 h in a temperature and humidity controlled incubator (37 °C, 95 % relative humidity and 5 % CO₂). At predetermined time points, the plates were equilibrated to room temperature for 30 min. The incubated solutions were discarded and the cells were washed twice with 1×PBS. Then, 50 μ l of both 1×PBS and CellTiter-Glo® reagent were added to the wells. The plates were protected from light with aluminum foil and placed on an orbital shaker for 2 min before luminescence measurement with Varioskan LUX multimode microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). All measurements were done in quadruplicate.

Furthermore, the total protein content in each sample was quantified using the colorimetric bicinchoninic acid (BCA) assay (Pierce, Thermo Fisher Scientific, Waltham, MA, USA). The procedures were carried out according to the manufacturer protocol. Cell lysates (25 μ l each) from the cytotoxicity assay was transferred to a new 96-well plate. Working reagent (200 μ l) was subsequently added to each sample at a 1:8 ratio. The plates were kept in dark with aluminum foil and gently mixed on an orbital shaker for 30 seconds before proceeding to incubate at 37 °C for 30 min. The absorbance was read at 562 nm on a plate reader and the protein content was determined against a bovine serum albumin (BSA) standard curve (0–2000 μ g/ml). The total protein content results were used to normalize the cell viability from the CellTiter-Glo® assay by dividing the luminescence value in each sample by the total protein content (μ g) in the same sample before the statistical significance of the mean viability was determined using unpaired Student's *t*-test against the negative control for cell viability.

2.4 GLUT1 affinity and cellular uptake studies

CAL 27 squamous cell carcinoma cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) or supplied by the University of Helsinki. The CAL 27 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM; Gibco, ThermoFisher Scientific, Waltham, MA, USA) supplemented with L-glutamine (2.0 mM; ThermoFisher Scientific, Waltham, MA, USA), heat-inactivated fetal bovine serum (10 %; Gibco, ThermoFisher Scientific, Waltham, MA, USA), penicillin (50 U/ml)- streptomycin (50 μ g/ml) solution (ThermoFisher Scientific, Waltham, MA, USA). The CAL 27 cells (passages 7–20) were seeded at the density of 5 x 10⁵ cells/wells onto 24-well plates. The cells were used in the affinity and uptake studies two days after seeding. The culture medium was removed and the cells were washed with pre-warmed HBSS (Hank's balance salt solution) without glucose (pH 7.4). The cells were then incubated with HBSS at 37 °C for 10 min. before the experiments. Additional information on the experimental protocols is supplied in the supporting information.

In order to determine the ability of the compounds to bind to GLUT1 in the CAL 27 cell line, the cells were cultured, seeded and pre-incubated as described above. The HBSS was removed and the ability of the compounds to inhibit the uptake of the known GLUT1 substrate, [¹⁴C]-D-glucose (PerkinElmer, Waltham, MA, USA), was studied by incubating the cells at rt for 5 min. in a buffer with a pH 7.4 (250 μ l) and further containing 1.8 μ M (0.1 mCi/ml) of [¹⁴C]-D-glucose. The compounds were studied at concentrations ranging from 0.1–1800 μ M and the HBSS was used as a blank. After incubation, the experiment was ended by the addition of ice-cold HBSS and the cells were washed twice with ice-cold HBSS. The cells were then lysed with 250 μ l of 0.1 M sodium hydroxide, the lysate was mixed with 1.0 mL of Emulsifier safe cocktail (PerkinElmer, Waltham, MA, USA) and the radioactivity was measured by liquid scintillation counter (MicroBeta² counter,

PerkinElmer, Waltham, MA, USA). The inhibition of [¹⁴C]-D-glucose in the presence of the boron containing compounds compared to the control (HBSS) was calculated as percentages (%). See Supplementary Figure 44.

The concentration-dependent uptake studies of the glucoconjugates were performed by adding 10– 400 µM of the compounds in 250 µl of pre-warmed HBSS buffer on the cell layer. The incubation times for each compound were 5 min. and 30 min. After incubation the cells were washed and lysed as described above. The lysate from 4 wells was combined in a Eppendorf tube, centrifuged at 4°C, and 800 µl of the supernatant was collected and digested in 1.0 ml of conc. HNO₃ (TraceMetalTM grade, Fisher Chemical) for 24 h. After sample digestion, Milli-Q water (USF Elga Purelab Ultra) was added in order to reach a total volume of 10 ml and the boron concentrations were analyzed by inductively-coupled plasma mass spectrometry (ICP-MS).

The boron concentrations were analyzed by ICP-MS using a NeXION 350D ICP-MS instrument (PerkinElmer Inc., Waltham, MA, USA) and ESI PrepFAST autosampler (Elemental Scientific, Omaha, NE, USA). For sample injection a peristaltic pump and nebulizer were used. The instrument was operated with an RF power of 1.6 kW and with nebulizer gas, auxiliary gas, and plasma gas flows of 0.90, 18, and 1.2 l/min, respectively. The sample uptake rate was 3.5 ml/min and dwell times were set at 100 ms per AMU. To remove polyatomic interferences, a triple-quadrupole reaction system operating in collision mode with kinetic energy discrimination (KED) was used (with He as the cell gas (3.7 ml/min)). An internal standard, ⁸⁹Y, was mixed online with the samples to compensate for matrix effects and instrument drift. Boron was determined against a certified multi-element calibration standard (TraceCERT Periodic Table Mix 1, Sigma Aldrich) under acid conditions (6.7 % HNO₃, TraceMetalTM grade, Fisher Chemical). The calibration range used for ¹¹B was 4 – 400 μg/l

 and the detection limit (LOD) was 1.0 µg/l. Three replicates were obtained for each sample. The data was processed using the PerkinElmer Syngistix Data Analysis SoftwareTM.

3. Results

3.1 Synthesis and structural characterization of 6-O-carboranylmethyl glucoconjugates

The construction of the targeted glucoconjugates requires insights in boron cluster chemistry and carbohydrate chemistry. A significant amount of progress has been achieved in both areas over a considerable timespan and robust reaction methodologies can be found in the existing literature.^{23,24} Yet, each new synthetic target requires the development of a suitable strategy and, unlike the 3-*O*-carboranylmethyl⁴⁰, the carboranylmethyl-glucosides⁴¹ and other types of glucoconjugates previously evaluated,^{23,42,43} the 6-*O*-carboranylmethyl glucoconjugates (Figure 2) have been explicitly designed for clinical BNCT of head and neck cancers. The methyl glucopyranosides were included in order to evaluate if there is a difference between the affinity and cellular uptake of the two anomers since the hemiacetal exists as a mixture of both. In addition, the methyl group is minimally intrusive which is beneficial since information on the substrate tolerance of GLUT1 is limited.⁴⁴

It was important to account for the susceptibility of decaborane to free hydroxyl groups and the possibility for carboranes to undergo degradation under strongly basic conditions when planning the synthesis of the 6-*O*-carboranylmethyl glucoconjugates. With these issues in mind, we developed the multistep synthetic routes to the three 6-*O*-carboranylmethyl glucoconjugates **1**, **2** and **3**. The synthesis and structural characterization discussion will herein be limited to glucoconjugate **1** (Scheme 1). The reaction routes to **2** and **3** are displayed in Supplementary scheme 1 and the synthesis and characterization of **2** and **3**, and all intermediates on these routes, were conducted in a similar fashion as described below for **1**.



Scheme 1. Reaction route leading to 1: i) 1) TBDMSCl, pyridine, rt, 24 h, 69 %; 2) BnBr, NaH, DMF, rt, 4 h, 88 %; ii) 1) HF-pyridine, THF, rt, 18 h, 99 %; 2) propargyl bromide, NaH, DMF, rt, 15 h, 83 %; iii) 1) B₁₀H₁₄, acetonitrile, 60 °C, 1 h; 2) **5**, toluene, 80 °C, 16 h, 55 %; iv) H₂, 10 % Pd/C, EtOAc:MeOH 7:1, 3–5 bar, rt, 4–6 h, 79 %.

In short, the synthesis commenced from D-glucose. In the first step, the sterically least hindered primary hydroxyl group was temporarily protected as a bulky silyl ether with TBDMSCI in pyridine in an acceptable yield. The remaining hydroxyl groups were benzylated, through standard alkylation protocols,⁴⁵ using BnBr and NaH in an 88 % isolated yield. The temporary silyl protective group was removed with Olah's reagent in excellent yield,⁴⁶ followed by the alkylation of the unmasked hydroxyl group with propargyl bromide and NaH in an 87 % yield. The coupling between decaborane (B₁₀H₁₄) and the terminal alkyne was achieved by first forming a decaborane-ACN complex⁴⁷ followed by a substitution reaction with **5**. In the pioneering work of Tietze et al., which encompassed the synthesis of carboranyl *C*-glycosides, the removal of benzyl groups were reported to proceed in high yields (61%–quant.).⁴⁸ In our first attempts, we encountered challenges regarding the debenzylation reaction and D-glucose was formed in considerable amounts as a side product (>40 %). These observations were consistent regardless of the employed transition metal catalyst. While we did not optimize the reaction conditions fully, we did note that performing the reaction at a lower substrate concentration (40 mg/ml vs. 14 mg/ml) led to a marked increase in the isolated yields (59

Molecular Pharmaceutics

 $\% \rightarrow 79$ %). The isolated yields on the synthetic routes were high throughout and the overall yield for the synthesis of **1** was 22 %.

In order to understand how the glucoconjugates interact with GLUT1, insights on their structural properties were required. As a result, we performed a detailed conformational characterization of the synthesized molecules by NMR-spectroscopy (¹H, ¹³C, ¹¹B, 1D-TOCSY, DQF-COSY, ed-HSQC and HMBC) further coupled with spectral simulations by quantum mechanical optimization utilizing the PERCH peak research software. The ¹H NMR spectrum of **1** was challenging to solve because the hemiacetal exists as an anomeric mixture (59 $\% \alpha$, 41 $\% \beta$) and the signals overlap in several parts of the spectrum. In order to overcome these challenges, 1D-TOCSY was utilized.^{49,50} The well separated H-1 α (5.10 ppm) and H-1 β -protons (4.46 ppm) were irradiated and a mixing time of 300 ms was applied in order to assure the transfer of magnetization throughout the spin-systems. This experiment resulted in information on the chemical shifts of all proton signals on both residues. By the use of standard 2D-NMR techniques, all of the ¹H and ¹³C NMR signals of both anomers could be assigned. The coupling constants which provide information on the angles between adjacent protons, and constitutes the basis of a conformational characterization, could not be reliably extracted from the ¹H NMR spectra alone. By use of the PERCH-software, the ¹H NMR spectrum was simulated and the coupling constants were obtained. The coupling constants confirmed that the glucoconjugates exist primarily in the ${}^{4}C_{1}$ -conformation and that the gg and gt rotamers (C5-C6bond) are dominating in solution ($J_{H-5,H-6a} = 1.8-2.0$ Hz, $J_{H-5,H-6b} = 4.9-5.2$ Hz and $J_{H-6a,H-6b} = -11.3$ Hz).⁵¹

The last step on the road to a complete NMR-spectroscopic characterization was to confirm that the boron cluster had remained intact. To this end, we measured decoupled ¹¹B NMR spectra and the signals appearing in the 0 to -30 ppm region confirmed⁵² that the carboranyl cluster was indeed intact.

In addition, we assigned all the signals (carboranylmethyl moiety, protective groups and carbohydrate) in the ¹H and ¹³C NMR spectra of all compounds and verified their structural identity and purity also by high resolution mass spectrometry.

3.2 Experimental and computational GLUT1 affinity studies

We were interested in understanding how the glucoconjugates interact with GLUT1 since this provides the biochemical foundation for their potential use in the intended application. We sought inspiration from the previous work of Lippard et al. focusing on cytotoxic glucose-platinum conjugates.⁵³ While the requirements for a successful GLUT1 targeting approach is similar, there is a significant conceptual difference between the therapeutic approaches of using either non-toxic boron delivery agents (with a targeted external neutron beam) or delivery agents containing cytotoxic compounds since the glucoconjugates are likely to be transported into all cells expressing GLUT1 albeit in different amounts. In order to study the GLUT1 affinities of the glucoconjugates, an experimental cis-inhibition assay was devised using the human CAL 27 cell line. The CAL 27 cell line represents a head and neck cancer type amenable to treatment with BNCT. The overexpression of GLUT1 in CAL 27 is responsible for the aberrant growth of these tumors^{54,55} and therefore the GLUT1 targeting approach is warranted. Before conducting the assays, we validated the GLUT1 function of CAL 27 (see supporting information). The cis-inhibition assay was devised as a competition experiment between the glucoconjugates and [¹⁴C]-D-glucose, with D-glucose serving as a control. This experiment accurately mimics the situation that the delivery agents would face in a biological context. It has been previously speculated and shown that 6-O-substituted glucoconjugates display a higher affinity to GLUT1 than free D-glucose.^{53,56} In our current study, the affinities for the glucoconjugates 1-3 were in the low μ M range in contrast to the low mM-affinity displayed by free D-glucose. The exact GLUT1 IC₅₀-values were determined to be 43.96 μ M for 1, 262.4 μ M for 2, 15.2 μ M for 3 and >1mM for free D-glucose. The 4–67 times stronger affinity displayed by the

Molecular Pharmaceutics

glucoconjugates confirm that at least glucoconjugates **1** and **3** are capable of targeting GLUT1 in the intended application despite the high glucose levels found in blood (6 mM).

In order to elucidate the interactions between the glucoconjugates and the transporters on a molecular level, we next turned to molecular modelling. We focused on the differences in binding to GLUT1 and studied the protein-ligand interactions of the glucoconjugates 1-3 in the outward- and inward-open conformations of the transporter, i.e., on the outside and inside of the cell. To set up a computational model, an experimental structure of the transporter was required. However, only the crystal structure of the inward-open conformation of GLUT1 has been reported⁵⁷. In order to perform the docking studies on equal footing for both the inward and outward-open conformations, we created a model based on XylE, a D-xylose-proton symporter found in *E.coli* for which crystal structures of both the inward-open (PDB ID 4QIQ),⁵⁸ and outward open (PDB ID 6N3I)⁵⁹ conformations exist. XylE is structurally very similar to the GLUT1-4 proteins (29% sequence identity and 49% similarity).⁶⁰ Importantly, the binding site residues are identical to GLUT1 except for the Gln415 in XylE which is Asn411 in GLUT1.^{61,62} After virtual mutation of this residue, we estimated binding energies by molecular docking studies. In our models, the glucoconjugates 1-3 bind significantly stronger to both the outward- and inward-open binding sites of the transporter than D-glucose, in line with the experimental observations above. For the outward-open conformation, the binding free energy difference is estimated to be up to 5 kcal/mol in favor of the glucoconjugates, corresponding to a binding affinity increase on the order of 10^3 (see supporting information for details).





Figure 3. Glucoconjugate 3 bound to the outward-open conformation of the transporter. Top: Green areas indicate intramolecular non-covalent interactions between 3 and the protein. Bottom: The closest amino acids surrounding the ligands, using PDB 6N3I numbering; hydrogen bonds shown as blue dashes, the binding pose of β -Glc superimposed in green color over the glucoconjugate.

There are a few observations of importance from the BNCT delivery agent perspective. The estimated binding affinity of each glucoconjugate is an order of magnitude lower in the inward-open binding pocket than in the corresponding outward-open one, that is, the ligand binds more tightly on the outside. This is beneficial from a functional point-of-view, as it implies that after the conformational change of the protein from the outward-open to the inward-open conformation, the

Molecular Pharmaceutics

ligand is more readily released to the inside of the cell. For D-glucose, this difference in binding energy between the inward- and outward-open conformations is absent.

For the outward-open structure, two major binding poses for the glucoconjugates were identified. In one, the sugar end of the glucoconjugate overlaps with the most favorable binding pose of free glucose, while the carboranyl end extends towards the hydrophobic end of the binding pocket, see Figure 3. This agrees with the hydrophobic nature of the carboranes,²² as manifested by the almost neutral partial atomic charges of both boron and hydrogen in the B—H bonds (see supplementary information). In the second pose, the glucoconjugate is slightly rotated. This pose is estimated to bind with practically equal affinity (see Table S1).

In general, the binding pocket seems rather accommodating from a structural point-of-view, with enough space for the bulky carboranylmethyl substituent at the 6th position in addition to the sugar. In order to corroborate this, we performed a quantum mechanical non-covalent interaction (NCI) analysis³⁴ on the ligand/transporter complex. The analysis revealed favorable interactions between ligand and protein at both ends of the glucoconjugate (Figure 3, top). Importantly, no repulsive intramolecular steric interactions are identified; even the largest of the boron cluster conjugates fits snugly to the transporter pocket. The inward-open conformation, on the other hand, displays greater flexibility in the binding site, which leads to a number of binding poses for both glucose and the glucoconjugates. This might also explain the lower binding affinity for the glucoconjugates to this site.

3.3 Cytotoxicity and cellular uptake studies

With the biochemical foundations of the GLUT1 targeting approach investigated, we continued by addressing the cellular uptake and cytotoxicity of the glucoconjugates since these are essential properties

of boron delivery agents and important factors for eventual translation into the clinics. The CAL 27 cell line was used in these studies because of its clinical relevance. In the cytotoxicity assays, the glucoconjugates **1**, **2** and **3** were incubated with the cells at concentrations of 5 μ M, 25 μ M, 50 μ M, 125 μ M and 250 μ M for 6 h and 24 h. These concentrations were chosen based on the affinity results and the time points were selected with the clinical perspective related to intravenous administration of the boron carriers in mind. In these studies, the clinically deployed BSH was used as a reference. BPA was omitted because its IC₅₀-value has been previously reported to be in the low mM range.¹⁴ The cell viability was quantified by the detection of ATP metabolic activity-generated luminescence from the viable cells after incubation using a commercially available Cell-Titer Glo assay. The glucoconjugates **1–3** displayed IC₅₀-values in the μ M-range and were consistently less toxic than BSH. The IC₅₀-values were obtained from nonlinear regression fitting of the cell viability data and were found to be: 214.8 μ M for **1**, 196.1 μ M for **2**, 276.6 μ M for **3** and 98.7 μ M for BSH (see Figure 4). From a toxicity standpoint, there is therefore no objection to their use as delivery agents in BNCT.



Figure 4. Cell cytotoxicity studies in CAL 27 cells after incubation with negative (cell culture medium) and positive (1% Triton X-100) controls, and glucoconjugates **1**, **2**, **3**, and BSH at 5 μ M, 25 μ M, 50 μ M, 125 μ M and 250 μ M for 6 and 24 h. Error bars represent the mean \pm s.d. (n=4) in comparison with the negative control. The statistical hypothesis was evaluated by unpaired Student's *t*-test where the significant probabilities were set at **p* < 0.05, ***p* < 0.01 and ****p* < 0.001.

Our final focus in this study was to determine if the glucoconjugates are transported into the cells through GLUT1 or if they, at the very least, remain attached to the cells. This is within the critical range required in clinical BNCT for the generated alpha particles to exert a cell-killing effect. This information was obtained by determining the boron content in the CAL 27 cell lysates after incubation with the compounds and careful washing. The development of a functioning protocol featuring suitable incubation times, compound concentrations, work-up protocols and methods for the robust analysis of boron content required an extensive number of trials. In the end, incubation times of 5 min. and 30 min. were selected based on the optimal performance of [¹⁴C]-D-glucose under these conditions, and, the concentration range 10 μ M – 400 μ M was selected based on the GLUT1 affinity results. The ICP-MS instrument used in determination of the boron content was found to be somewhat insensitive and cells from four wells were combined and digested in order to obtain results of high reliability. The results are summarized in Figure 5.



Figure 5. Cell uptake studies in the CAL 27 cell line after incubation with glucoconjugates 1 (\blacktriangle), 2 (\blacksquare), 3 (\bullet), BPA (\bullet) and BSH (\blacktriangledown) in the 10–400 µM-range for 5 min. (A; n=3) and 30 min. (B; n=3). The Michaelis-Menten kinetic parameters for glucoconjugates when available; at 5 min. incubation time (A), glucoconjugate 2: $V_{max} = 2.791$; $K_m = 80.49$. At 30 min. incubation time (B), glucoconjugate 1: $V_{max} = 16.29$; $K_m = 630.5$, glucoconjugate 2: $V_{max} = 6.417$; $K_m = 488.3$, glucoconjugate 3: $V_{max} = 16.89$; $K_m = 894.2$ and BPA: $V_{max} = 3.625$; $K_m = 3737$.

In addition to studying the uptake of glucoconjugates 1–3, both BSH and BPA were included as representatives of delivery agents in clinical use. All glucoconjugates delivered a significantly higher boron content to the CAL 27 cells than BPA and BSH across the entire concentration range. To a certain degree, the observations may be explained by the different uptake mechanisms of the glucoconjugates, BPA, and BSH. Nevertheless, according to our preliminary assessment, targeting GLUT1 translates into a competitive strategy for BNCT – outperforming the passive transport of BSH and the LAT1-targeting approach of BPA in the *in vitro* cellular uptake model used. Glucoconjugates 1 and 3 were found to have the best boron delivery capacity, with 3 being slightly better at the 5 min. mark and 1 being considerably better at the 30 min. mark. We note that the correlation to the GLUT1 affinity results is perhaps weaker than one would expect. The difference is natural when considering that the two methods provide *complementary* insights on two separate properties: the ability to compete with other GLUT1 substrates for the transporter and the ability to remain attached to the cell or internalized.

Lastly, in order to distinguish which of our two prime candidates, glucoconjugates 1 and 3, would be better suited for future *in vivo* and potential preclinical BNCT studies, we determined their aqueous solubility. This is an important factor from the formulation and treatment perspective, as exemplified by BPA which is administered as a fructose complex due to the low aqueous solubility of BPA itself. Surprisingly, glucoconjugate 1 displayed a significantly higher aqueous solubility than 3 (1 mg/ml vs. < 1 mg/500 ml). When this property is further coupled with its high GLUT1 affinity, low cytotoxicity and outstanding *in vitro* delivery capacity, we are pleased to report that 6-*O*-(*ortho*carboranylmethyl)-D-glucopyranose, our "Trojan horse", has considerable potential as a delivery agent for BNCT.

4. Discussion

Head and neck cancers account for up to 10 % of all cancers and the recurrent ones are accompanied by a poor survival rate in patients.³ BNCT has been successfully applied to the treatment of head and neck cancers^{63,64} and is currently attracting large investments on a global scale due to the recent development of in-hospital neutron accelerators which is a game-changer from a patient treatment perspective.

In this work, we have designed and synthesized molecular-scale "Trojan horses", i.e. conjugates of glucose and boron clusters containing a high boron content, and studied the biochemical foundations of a GLUT1-targeting strategy to BNCT. In more detail, we have used a chemistry-based approach featuring both experimental and computational methodologies. From the onset, important factors such as the possible interference with glucose metabolism through the glycolysis route was accounted for. In addition to addressing the biochemical foundations of this approach, we have identified a hit molecule which displays good cytocompatibility, sufficient aqueous solubility and high cellular uptake in the relevant human CAL 27 head and neck cancer cell line. In our in vitro assessment, glucoconjugate 1 was able to outperform the current delivery agents in clinical use (BPA and BSH) in terms of boron delivery capacity while simultaneously having a sufficiently high affinity to GLUT1 to permit competition with the high levels of glucose found in blood. Therefore, in addition to providing a missing link on the biochemical foundations of a GLUT1-targeting strategy to BNCT – we have identified a potentially promising new glucoconjugate for clinical BNCT. With the solid basis reported herein, the development of a suitable formulation featuring the ¹⁰B-enriched version of glucoconjugate 1 with accompanied in vivo-testing is soon to follow. The results from these studies will be reported in due course.

Supporting information is available. The supporting information contains: information on additional synthetic routes, NMR-spectra of the synthesized compounds, details on the molecular docking studies and ligand PDBQT files, as well as additional information on the characterization of the GLUT1 function in the CAL 27 cell line and affinity/uptake studies.

6. Acknowledgments

PhD. Jussi Kärkkäinen (University of Eastern Finland), BSc. Ronja Rättö (University of Helsinki) and Mr. Joonas Waaramaa (University of Helsinki) are acknowledged for laboratory assistance and Prof. Hélder A. Santos and Ms. Alexandra Correia (University of Helsinki) for their contributions to the cytotoxicity studies. CSC-The Finnish IT Center for Science and the Finnish Grid and Cloud Infrastructure (urn:nbn:fi:research-infras-2016072533) are acknowledged for providing the computational resources required for this work. Further, the authors are grateful for financial support from the Jane and Aatos Erkko foundation, the Cancer foundation, the Swedish Cultural foundation, the Ruth and Nils-Erik Stenbäck foundation, the Finnish Academy of Science and Letters, the University of Helsinki research funds, the Academy of Finland (projects: 308329, 318422, 289179, and 319453), and the Waldemar von Frenckell foundation.

7. Author contributions

F.S.E and O.A. conceived the idea and F.S.E. designed the project and led the initiate with input from O.A., A.A., M.P.J., M.S. and J.R. J.M., H.C.B., R.M.F. and F.S.E. contributed to the synthesis and structural characterization of the glucoconjugates. M.S. and S.I. were responsible for the cytotoxicity testing. M.P.J. and I.K.S. were responsible for the molecular modelling aspects and

analysis. J.J., K.H., J.T., S.P. and J.R. were responsible for the experimental affinity and cellular uptake studies. The manuscript was written with contributions from all authors.

8. Competing interests' statement

There are no competing interests associated with this work.

9. References

- Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global Cancer Statistics, 2002. CA. Cancer J. Clin. 2005, 55 (2), 74–108.
- Vigneswaran, N.; Williams, M. D. Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis. *Oral Maxillofac. Surg. Clin. N. Am.* 2014, *26* (2), 123–141.
- Wong, L. Y.; Wei, W. I.; Lam, L. K.; Yuen, A. P. W. Salvage of Recurrent Head and Neck Squamous Cell Carcinoma after Primary Curative Surgery. *Head Neck* 2003, 25 (11), 953– 959.
- (4) Beck, A.; Goetsch, L.; Dumontet, C.; Corvaïa, N. Strategies and Challenges for the next Generation of Antibody–Drug Conjugates. *Nat. Rev. Drug Discov.* **2017**, *16* (5), 315–337.
- (5) Yuan, T.-Z.; Zhan, Z.-J.; Qian, C.-N. New Frontiers in Proton Therapy: Applications in Cancers. *Cancer Commun.* 2019, 39 (1), 61.
- Yock, T. I.; Tarbell, N. J. Technology Insight: Proton Beam Radiotherapy for Treatment in Pediatric Brain Tumors. *Nat. Clin. Pract. Oncol.* 2004, *1* (2), 97–103.
- (7) Hosmane, N. S. Boron Science: New Technologies and Applications; CRC Press, 2011.
- Locher, G. L. Biological Effects and Therapeutic Possibilities of Neutrons. *Am. J. Roentgenol Radium Ther.* 1936, *36*, 1–13.

- (9) Barth, R. F.; Zhang, Z.; Liu, T. A Realistic Appraisal of Boron Neutron Capture Therapy as a Cancer Treatment Modality. *Cancer Commun.* 2018, 38 (1), 36.
- (10) Kreiner, A. J.; Bergueiro, J.; Cartelli, D.; et al. Present Status of Accelerator-Based BNCT.
 Rep. Pract. Oncol. Radiother. 2016, 21 (2), 95–101.
- Barth, R. F.; Mi, P.; Yang, W. Boron Delivery Agents for Neutron Capture Therapy of Cancer.
 Cancer Commun. 2018, 38 (1), 35.
- (12) Soloway, A. H.; Tjarks, W.; Barnum, B. A.; et al. The Chemistry of Neutron Capture Therapy. *Chem. Rev.* 1998, *98* (4), 1515–1562.
- (13) Hey-Hawkins, E.; Teixidor, C. V. Boron-Based Compounds: Potential and Emerging Applications in Medicine; John Wiley & Sons, 2018.
- (14) Nemoto, H.; Cai, J.; Iwamoto, S.; Yamamoto, Y. Synthesis and Biological Properties of Water-Soluble p-Boronophenylalanine Derivatives. Relationship between Water Solubility, Cytotoxicity, and Cellular Uptake. *J. Med. Chem.* 1995, *38* (10), 1673–1678.
- (15) Kankaanranta, L.; Seppälä, T.; Koivunoro, H.; et al. L-Boronophenylalanine-Mediated Boron Neutron Capture Therapy for Malignant Glioma Progressing After External Beam Radiation Therapy: A Phase I Study. *Int. J. Radiat. Oncol.* **2011**, *80* (2), 369–376.
- Wittig, A.; Collette, L.; Appelman, K.; et al. EORTC Trial 11001: Distribution of Two ¹⁰ B-Compounds in Patients with Squamous Cell Carcinoma of Head and Neck, a Translational Research/Phase 1 Trial. *J. Cell. Mol. Med.* 2009, *13* (8b), 1653–1665.
- (17) Trivillin, V. A.; Garabalino, M. A.; Colombo, L. L.; et al. Biodistribution of the Boron Carriers Boronophenylalanine (BPA) and/or Decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an Experimental Model of Lung Metastases. *Appl. Radiat. Isot.* 2014, *88*, 94–98.
- (18) Szablewski, L. Expression of Glucose Transporters in Cancers. *Biochim. Biophys. Acta BBA Rev. Cancer* 2013, *1835* (2), 164–169.

 (19) Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. *Science* 2009, *324* (5930), 1029–1033.

- (20) Warburg, O. On the Origin of Cancer Cells. *Science* **1956**, *123* (3191), 309–314.
- (21) König, M.; Bulik, S.; Holzhütter, H.-G. Quantifying the Contribution of the Liver to Glucose Homeostasis: A Detailed Kinetic Model of Human Hepatic Glucose Metabolism. *PLoS Comput. Biol.* 2012, 8 (6), e1002577.
- (22) Stockmann, P.; Gozzi, M.; Kuhnert, R.; et al. New Keys for Old Locks: Carborane-Containing Drugs as Platforms for Mechanism-Based Therapies. *Chem. Soc. Rev.* 2019, *48* (13), 3497–3512.
- (23) Satapathy, R.; Dash, B. P.; Mahanta, C. S.; et al. Glycoconjugates of Polyhedral Boron Clusters. J. Organomet. Chem. 2015, 798, 13–23.
- (24) Luderer, M. J.; de la Puente, P.; Azab, A. K. Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy. *Pharm. Res.* 2015, *32* (9), 2824–2836.
- Bar-Even, A.; Flamholz, A.; Noor, E.; Milo, R. Rethinking Glycolysis: On the Biochemical Logic of Metabolic Pathways. *Nat. Chem. Biol.* 2012, *8* (6), 509–517.
- (26) Staroverov, V. N.; Scuseria, G. E.; Tao, J.; Perdew, J. P. Comparative Assessment of a New Nonempirical Density Functional: Molecules and Hydrogen-Bonded Complexes. *J. Chem. Phys.* 2003, *119* (23), 12129–12137.
- (27) Grimme, S.; Antony, J.; Ehrlich, S.; Krieg, H. A Consistent and Accurate *Ab Initio* Parametrization of Density Functional Dispersion Correction (DFT-D) for the 94 Elements H-Pu. *J. Chem. Phys.* 2010, *132* (15), 154104.
- (28) Becke, A. D.; Johnson, E. R. A Density-Functional Model of the Dispersion Interaction. J. Chem. Phys. 2005, 123 (15), 154101.

- Weigend, F.; Ahlrichs, R. Balanced Basis Sets of Split Valence, Triple Zeta Valence and Quadruple Zeta Valence Quality for H to Rn: Design and Assessment of Accuracy. *Phys. Chem. Chem. Phys.* 2005, 7 (18), 3297.
- (30) Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A Well-Behaved Electrostatic Potential Based Method Using Charge Restraints for Deriving Atomic Charges: The RESP Model. J. Phys. Chem. 1993, 97 (40), 10269–10280.
- (31) Ahlrichs, R.; Bär, M.; Häser, M.; et al. Electronic Structure Calculations on Workstation Computers: The Program System Turbomole. *Chem. Phys. Lett.* **1989**, *162* (3), 165–169.
- (32) Eichkorn, K.; Weigend, F.; Treutler, O.; Ahlrichs, R. Auxiliary Basis Sets for Main Row Atoms and Transition Metals and Their Use to Approximate Coulomb Potentials. *Theor. Chem. Acc.* 1997, 97 (1–4), 119–124.
- (33) Valiev, M.; Bylaska, E. J.; Govind, N.; et al. NWChem: A Comprehensive and Scalable Open-Source Solution for Large Scale Molecular Simulations. *Comput. Phys. Commun.* 2010, *181* (9), 1477–1489.
- (34) Johnson, E. R.; Keinan, S.; Mori-Sánchez, P.; et al. Revealing Noncovalent Interactions. J. Am. Chem. Soc. 2010, 132 (18), 6498–6506.
- (35) Contreras-García, J.; Johnson, E. R.; Keinan, S.; et al. NCIPLOT: A Program for Plotting Noncovalent Interaction Regions. J. Chem. Theory Comput. 2011, 7 (3), 625–632.
- (36) Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A Semiempirical Free Energy Force Field with Charge-Based Desolvation. *J. Comput. Chem.* 2007, 28 (6), 1145–1152.
- (37) Morris, G. M.; Huey, R.; Lindstrom, W.; et al. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. *J. Comput. Chem.* **2009**, *30* (16), 2785–2791.
- (38) Oda, A.; Fukuyoshi, S.; Nakagaki, R.; Takahashi, O. Determination of AMBER Force Field Parameters for Thioester by Quantum Chemical Calculations. *Chem. Lett.* 2013, *42* (10), 1206– 1208.

2	
3	
4	
5	
6	
7	
, 0	
0	
9	
10	
11	
12	
13	
14	
14	
15	
16	
17	
18	
19	
י. הר	
∠∪ ว1	
21	
22	
23	
24	
25	
25 76	
20	
27	
28	
29	
30	
21 21	
ינ רכ	
32	
33	
34	
35	
36	
37	
27 20	
20 20	
39	
40	
41	
42	
43 43	
ر. ۸۸	
-+4 4 -	
45	
46	
47	
48	
49	
50 50	
50 E 1	
5 I	
52	
53	
54	
55	
56	
5/ 52	
58	
59	
60	

(39)	Couto, M.; García, M. F.; Alamón, C.; et al. Discovery of Potent EGFR Inhibitors through the
	Incorporation of a 3D-Aromatic-Boron-Rich-Cluster into the 4-Anilinoquinazoline Scaffold:
	Potential Drugs for Glioma Treatment. Chem Eur. J. 2018, 24 (13), 3122–3126.

- (40) Tjarks, W.; Anisuzzaman, A. K. M.; Liu, L.; et al. Synthesis and in Vitro Evaluation of Boronated Uridine and Glucose Derivatives for Boron Neutron Capture Therapy. *J. Med. Chem.* 1992, *35* (9), 1628–1633.
- (41) Tietze, L. F.; Bothe, U. Ortho-Carboranyl Glycosides of Glucose, Mannose, Maltose and Lactose for Cancer Treatment by Boron Neutron-Capture Therapy. **1998**, *4* (7), 1179–1183.
- (42) Satapathy, R.; Dash, B. P.; Bode, B. P.; et al. New Classes of Carborane-Appended 5-Thio-D-Glucopyranose Derivatives. *Dalton Trans.* 2012, *41* (29), 8982–8988.
- (43) Hosmane, N. S.; Eagling, R. Handbook of Boron Science; World Scientific (Europe), 2018.
- (44) Zhao, F.-Q.; Keating, A. Functional Properties and Genomics of Glucose Transporters. *Curr. Genomics* 2007, 8 (2), 113–128.
- (45) Ekholm, F. S.; Ardá, A.; Eklund, P.; et al. Studies Related to Norway Spruce Galactoglucomannans: Chemical Synthesis, Conformation Analysis, NMR Spectroscopic Characterization, and Molecular Recognition of Model Compounds. *Chem. Eur. J.* 2012, *18* (45), 14392–14405.
- (46) Olah, G. A.; Welch, J. T.; Vankar, Y. D.; et al. Synthetic Methods and Reactions. 63.
 Pyridinium Poly(Hydrogen Fluoride) (30% Pyridine-70% Hydrogen Fluoride): A Convenient Reagent for Organic Fluorination Reactions. J. Org. Chem. 1979, 44 (22), 3872–3881.
- (47) Valliant, J. F.; Guenther, K. J.; King, A. S.; et al. The Medicinal Chemistry of Carboranes. *Coord. Chem. Rev.* 2002, 232 (1–2), 173–230.
- (48) Tietze, L. F.; Griesbach, U.; Schuberth, I.; et al. Novel Carboranyl C-Glycosides for the Treatment of Cancer by Boron Neutron Capture Therapy. *Chem. Eur. J.* 2003, *9* (6), 1296–1302.

- (49) Ekholm, F. S.; Sinkkonen, J.; Leino, R. Fully Deprotected β-(1→2)-Mannotetraose Forms a Contorted α-Helix in Solution: Convergent Synthesis and Conformational Characterization by NMR and DFT. *New J. Chem.* 2010, *34* (4), 667.
- (50) Berger, S.; Braun, S. 200 and More NMR Experiments: A Practical Course, 3rd rev. and expanded ed.; Wiley-VCH: Weinheim, 2004.
- (51) Stenutz, R.; Carmichael, I.; Widmalm, G.; Serianni, A. S. Hydroxymethyl Group Conformation in Saccharides: Structural Dependencies of ² J_{HH}, ³ J_{HH}, and ¹ J_{CH} Spin–Spin Coupling Constants. J. Org. Chem. 2002, 67 (3), 949–958.
- (52) Hermanek, S. Boron-11 NMR Spectra of Boranes, Main-Group Heteroboranes, and Substituted Derivatives. Factors Influencing Chemical Shifts of Skeletal Atoms. *Chem. Rev.* 1992, 92 (2), 325–362.
- (53) Patra, M.; Johnstone, T. C.; Suntharalingam, K.; Lippard, S. J. A Potent Glucose-Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer Cells. *Angew. Chem. Int. Ed.* **2016**, *55* (7), 2550–2554.
- (54) Wang, Y.-D.; Li, S.-J.; Liao, J.-X. Inhibition of Glucose Transporter 1 (GLUT1) Chemosensitized Head and Neck Cancer Cells to Cisplatin. *Technol. Cancer Res. Treat.* 2013, *12* (6), 525–535.
- (55) Li, S.; Yang, X.; Wang, P.; Ran, X. The Effects of GLUT1 on the Survival of Head and Neck
 Squamous Cell Carcinoma. *Cell. Physiol. Biochem.* 2013, *32* (3), 624–634.
- (56) Gynther, M.; Ropponen, J.; Laine, K.; et al. Glucose Promoiety Enables Glucose Transporter Mediated Brain Uptake of Ketoprofen and Indomethacin Prodrugs in Rats. *J. Med. Chem.*2009, *52* (10), 3348–3353.
- (57) Deng, D.; Xu, C.; Sun, P.; et al. Crystal Structure of the Human Glucose Transporter GLUT1.
 Nature 2014, *510* (7503), 121–125.

2	
1	
4	
5	
6	
7	
8	
9	
10	
11	
12	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20	
∠ I วา	
22	
23	
24	
25	
26	
27	
28	
20	
29	
30	
31	
32	
33	
34	
35	
36	
37	
20	
38	
39	
40	
41	
42	
43	
44	
45	
46	
40	
4/	
48	
49	
50	
51	
52	
53	
54	
5-	
55	
56	
57	
58	
59	

60

(58) Wisedchaisri, G.; Park, M.-S.; Iadanza, M. G.; et al. Proton-Coupled Sugar Transport in the Prototypical Major Facilitator Superfamily Protein XylE. *Nat. Commun.* **2014**, *5* (1), 4521.

- (59) Jiang, X.; Wu, J.; Ke, M.; et al. Engineered XylE as a Tool for Mechanistic Investigation and Ligand Discovery of the Glucose Transporters GLUTs. *Cell Discov.* 2019, 5 (1), 14.
- (60) Sun, L.; Zeng, X.; Yan, C.; et al. Crystal Structure of a Bacterial Homologue of Glucose Transporters GLUT1–4. *Nature* 2012, 490 (7420), 361–366.
- (61) Deng, D.; Sun, P.; Yan, C.; et al. Molecular Basis of Ligand Recognition and Transport by Glucose Transporters. *Nature* 2015, *526* (7573), 391–396.
- (62) Park, M.-S. Molecular Dynamics Simulations of the Human Glucose Transporter GLUT1.
 PLOS ONE 2015, *10* (4), e0125361.
- (63) Kankaanranta, L.; Seppälä, T.; Koivunoro, H.; et al. Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial. *Int. J. Radiat. Oncol.* 2012, 82 (1), e67–e75.
- (64) Wang, L.-W.; Chen, Y.-W.; Ho, C.-Y.; et al. Fractionated Boron Neutron Capture Therapy in Locally Recurrent Head and Neck Cancer: A Prospective Phase I/II Trial. *Int. J. Radiat. Oncol.* 2016, *95* (1), 396–403.